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manufacturing licences in 
place at year end – 135 for 
human medicines and 24 for 
veterinary medicines
159
delegates attended the 
HPRA Brexit information 
day in February
The number of Reference Member 
State transfers to Ireland for 
human and veterinary medicines 
in advance of Brexit
554
new human medicines 
authorised during 2019
applications issued for clinical 
trials of human medicines
433
88
medical devices organisations 
registering with the HPRA as 
EU Authorised Representatives 
following impact of Brexit 
40
HPRA experts acted as rapporteur or  
co-rapporteur in respect of 24 new 
centrally authorised veterinary medicines 
24 
The number of European 
Medicines Agency scientific advice 
procedures for human medicines 




at a Glance 
 
 
Top 5  
export certificates issued – 
1,367 certificates for medicines 




The HPRA was among the top five 
contributors at EU level for lead 
assessment of centrally authorised 
medicines & scientific advice
GMP inspections conducted at 
manufacturing sites for human and 
veterinary medicines, and active 
substances 
110
The HPRA was EU rapporteur for 
the management of any safety 
signals detected in relation to 
55 centrally authorised human 
medicines 
55
medical device vigilance reports 
received and assessed
2,295
market surveillance cases 
undertaken in respect of 
medical devices
dosage units of fake 




medicine recalls consisting  
of 125 human medicines and  
7 veterinary medicines
132
reports of suspected adverse 
reactions associated with use of 
veterinary medicines
347 
suspected adverse reaction 
reports for human medicines 
received
9,253
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3
page views on the HPRA 
website – the  highest 




reactive surveillance cases 
initiated for cosmetic products
287 i
It is with great pleasure that I present the 
2019 annual report of the Health Products 
Regulatory Authority (HPRA). Without 
doubt, this was a year that brought 
many new developments and changes 
within both the internal and external 
environments. I am immensely proud 
of the way the organisation planned for 
and adapted to the opportunities and 
challenges that presented during the year, 
while steadfastly maintaining its primary 
focus on the protection of public and 
animal health. 
Preparing for Brexit
A key area of focus for the agency during the year was 
its planning for Brexit in the context of the high profile 
deadlines in place and set against the uncertain 
political backdrop that ensued beyond our shores. 
The HPRA showed great leadership throughout this 
time, working closely with our partners across the 
health sector to ensure minimum disruption to the 
continued supply and availability of medicines and 
medical devices for Irish patients. 
The HPRA’s focus centred on five key Brexit pillars, 
previously identified as part of its planning and 
contingency processes. These pillars, as set out 
below, served as the agency’s guiding principles 
as it implemented and delivered detailed Brexit 
preparations and provisions: 
1. Stakeholder engagement and communications;
2. Existing work where the UK is a lead member state;
3. Future work to be allocated;
4. Leadership/public health/advocacy;
5. Internal capability. 
At all stages, working in partnership with the 
Department of Health and the HSE, the HPRA worked 
to build collaboration and consensus with other 
stakeholders to ensure that we were appropriately 




In particular, there was a focus on delivering 
regulatory responsiveness and flexibility to aid swift 
actions to be taken as required. I am confident that 
with this high standard of preparedness, planning and 
engagement, we remain ready and well-positioned 
to manage any issues in relation to health product 
supply that could emerge when the UK fully exits 
the EU. No doubt, this will be a focus of my annual 
statement again for 2020.
Increasing our Contribution at a 
European Level
Another key development during 2019 was the 
change in profile and increase in the HPRA’s 
contribution to the centralised assessment procedures 
at the European Medicines Agency (EMA). By the end 
of the year, the agency became one of the top five 
contributors in terms of its work on lead assessments 
for centrally authorised medicines and scientific 
advice. This significantly enhanced contribution 
during 2019 represents the outcome of a series of 
planned measures, overseen by the Authority, which 
were introduced over the past number of years to 
increase the HPRA’s scientific expertise and refine our 
focus on supporting and enabling innovation. This 
ongoing prioritisation and investment will ensure that 
the HPRA continues to act as a lead agency within the 
centralised system that enables access to innovative 
treatments and medicines for Irish patients and all 
European citizens.  
A major highlight of the year was the appointment 
of our Chief Executive, Dr Lorraine Nolan, to 
the prestigious post of Vice-Chair of the EMA 
Management Board. This further demonstrates the 
HPRA’s commitment to supporting the European 
regulatory network for human and veterinary 
medicines and is a testament to Dr Nolan’s 
contribution and expertise.  
Other Changes within the 
Authority and Broader 
Organisation
At the close of 2019, we prepared for a notable 
change in the composition of our Authority when the 
most recent terms of two longstanding members, Pat 
Brangan and Wilf Higgins, came to an end. Both gave 
long, loyal and expert service to the workings of the 
Authority during their tenure. Pat additionally held the 
Chair both of the Advisory Committee for Veterinary 
Medicines and the Audit and Risk Committee, while 
Wilf was Chair of the Advisory Committee for Medical 
Devices. They were strong and effective contributors 
at our Authority meetings, not just across their 
respective areas of expertise, but in all deliberations 
and discussions. Both Pat and Wilf gave freely of their 
vast knowledge and experience, and provided huge 
dedication and commitment to public sector delivery 
in Ireland. I thank them both sincerely and pay tribute 
to them as valued members of the Authority.  
This year, we welcomed one new Authority Member, 
Professor David Kerins. David is already contributing 
effectively to the Authority and has taken on the 
role of Chair of the Advisory Committee for Human 
Medicines. 
We were very saddened during the year to hear 
of the untimely passing of our previous Chairman, 
Michael Hayes. Michael served as the Chairman of 
the Authority from 2011 to 2016 and was a strong 
leader and good friend to us all. Ar dheis Dé go raibh 
a anam.
Also in 2019, we also bade farewell to Dr Joan 
Gilvarry following her retirement from the role of 
Director of Human Products Monitoring. Dr Gilvarry 
provided over 25 years of service to the HPRA in a 
number of roles. Her professionalism and expertise 
was valued highly throughout her career by her 
colleagues within the HPRA.   
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The Future
Looking forward, the Authority is now overseeing 
the development of the HPRA’s Strategic Plan for 
the period 2021 to 2025. To fully inform and assist 
the process, we held a number of focussed strategy 
sessions at Authority and executive levels, while 
there has been significant engagement internally with 
staff and externally with a broad range of interested 
stakeholders. The outcome of this ongoing and 
extensive consultation process, which commenced in 
2019, will reflect the changing environment in which 
the HPRA operates and the evolving needs and 
requirements of the health products regulatory system 
of the future. 
The outcome of this extensive preparatory exercise 
will deliver a strategic roadmap setting out clearly 
how the HPRA will continue to evolve and progress 
as an organisation while delivering its key public and 
animal health objectives for the benefit of all our 
partners and stakeholders.  
This is an exciting period in the development of our 
national regulatory authority. The HPRA is privileged 
to oversee the regulation of a number of dynamic 
and innovative sectors in Ireland that play such a 
central role in the protection and enhancement of 
public and animal life not just nationally but right 
across the world. A key focus, as always, will be on 
facilitating the availability of medicines and medical 
devices. However, it is also recognised that the 
existing regulatory model must continually evolve and 
respond to an ever-changing environment where the 
latest technologies and product innovations, coupled 
with increasing access to data and intelligence, are 
driving the development of new life-changing and 
life-saving health products.  
As part of its ever-developing strategic vision, the 
HPRA will continue to build mutually beneficial 
partnerships with relevant agencies across the public 
sector, with regulators internationally and with 
patients and healthcare professionals. Significant 
and meaningful engagement with patients and 
the broader health sector is central to our future 
effectiveness and we will never lose sight of our core 
mission to work on behalf of all those who use and 
benefit from health products.  
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As always, it is a great pleasure to give  
my foreword to the HPRA’s annual report 
and to highlight the achievements of the 
year that has past.
The Decade in Review
2019 was not only a year during which our 
organisation had many successes, but it also saw 
the close of the decade. Reflecting on this ten-year 
period, we have seen a time of intense growth and 
development for our agency and a time during which 
many ambitions have been realised. The remit of the 
organisation expanded to include new areas such 
as scientific animal protection and monitoring of the 
safety and quality of organs used in transplantation. 
We also successfully adopted our new HPRA name 
and brand. This change was driven by the need to 
reflect the extensive range of our remit, which covers 
multiple health products, most notably medicines 
and medical devices.  
I believe the most striking developments for the 
HPRA in this time period have been on two fronts. 
The first relates to the emphasis we now place on 
collaboration in carrying out our role, which serves to 
ensure better outcomes in public and animal health 
protection. Those partnerships have been brought 
about by the development of positive working 
relations and approaches with multiple stakeholders 
including those with direct responsibility across 
government for health service delivery, healthcare 
professionals and patients.  
The second area where we have brought about 
significant progress is our positioning as an 
influential leader in both the European and global 
regulatory networks. We have invested strategically 
over the past decade in chosen areas of expertise 
and capability, and in our contribution to leading 
regulatory fora and structures at an international 
level. Through this, we have achieved leadership 
roles within the Heads of Medicines Agencies (HMA) 
network, the Competent Authorities for Medical 
Devices (CAMD) and various European Medicines 
Agency (EMA) scientific committees, task forces and 
working groups. We have also made very significant 
advancements in our contribution to EMA scientific 
assessment and inspection activities. On a personal 
level, I was very proud to be appointed as the Vice-
Chair of EMA’s Management Board during 2019. 
As we move forward in the post-Brexit era, our 
capability to influence and build positive working 
relationships with colleagues across the European 






As was the case for so many organisations, 2019 was 
a year characterised by our work in dealing with the 
numerous and unprecedented challenges presented 
by Brexit. I am extremely grateful for the extensive 
work done by colleagues from across the organisation 
in preparing for the various political deadlines 
throughout the year. At all stages, we remained fully 
committed to prioritising public health needs over all 
matters. Collaboration with both the Department of 
Health and the Health Service Executive (HSE), and 
engagement with industry stakeholders, were steadfast 
throughout and ensured our preparedness for all 
outcomes. As we look ahead to the end of 2020, we 
are confident in the investment we have made in Brexit 
preparations and that we are ready for the full UK exit 
regardless of how that may occur. 
Shortages Framework
One of the most important public health initiatives 
that the organisation has undertaken in recent years 
has been the framework we implemented to ensure 
enhanced management of medicines shortages 
nationally. Medicines shortages are an increasing 
trend for all countries regardless of size or economic 
positioning and are brought about through multiple 
factors. Our shortages framework operates by 
enhancing coordination across the various stakeholders 
that have a role in the management of shortages. Since 
its implementation, it has been highly successful in 
ensuring optimal outcomes for patients and protecting 
healthcare provision capability. Throughout 2019, 
our processes for managing shortages were further 
enhanced through the establishment of a forum 
between the HPRA, Department of Health and HSE 
to assess critical dependencies on medicines in the 
context of healthcare delivery in Ireland. As a result, 
we now have a new level of intelligence to support 
our work in the area of shortages to provide for better 
proactive management. This will be hugely beneficial 
for patients and our health system in the years ahead. 
Our People and Processes
As an organisation, we are fully committed to 
continued investment in everyone who works in 
the HPRA and in the systems and processes that 
support them. We place huge value on developing 
our internal capabilities as this is key to enabling our 
future progress. For the past number of years, we 
have placed significant emphasis on developing and 
expanding our scientific expertise and capability. This 
has been driven by a strategic objective to better 
support the pace of innovation in the sectors that 
we regulate and to increase our contribution to the 
centralised assessments of medicines co-ordinated by 
the EMA. In 2019, we were very proud to realise part 
of this objective after being ranked within the top five 
agencies contributing to the scientific assessments 
of both medicines for human use and medicines for 
veterinary use. Given the pace of innovation in the 
sectors that we regulate, the increasing trends of 
product complexity, digitalisation and convergence, 
and the sophistication in technology and processes, 
expanding expertise and skills will continue to be a 
focus for the HPRA.
During 2019, our change management programme for 
our medical device activities continued. The impetus 
for this programme has been enhanced positioning 
of our capabilities to regulate the highly innovative 
medtech sector and to prepare for the implementation 
of the new legislative framework for medical devices 
in Europe over the next three years. A number of key 
milestones were reached during the past 12 months, 
including the implementation and roll-out of a revised 
departmental structure based on technology streams. 
This provides a more dynamic and agile approach 
to resourcing, which positions us with improved 
capabilities in the context of product convergence 
and technology development. This overall approach 
represents a very exciting development in our internal 
resourcing model and is something we intend to 
replicate in other areas.
Another focus during the year was the roll-out of our 
ongoing technology project focused on enhancing 
our workflow capability. 2019 saw our medicines 
assessment activities incorporated into the new 
workflow system. We look forward to the opportunities 
ahead in 2020 and beyond as we work to develop 
a longer-term digital transformation strategy for the 
organisation. 
The health and wellbeing of our organisation is one 
of our greatest assets and we work hard to promote 
a positive working environment within the HPRA. 
This is part of our culture and central to our value 
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system. Some of our proudest achievements as an 
organisation last year included the launch of our 
Diversity and Inclusion Policy, which was supported by 
a number of focussed initiatives in this area. We were 
thrilled to have our work externally recognised with 
receipt of an Investors in Diversity award. In 2019, 
the HPRA also became a partner to See Change, a 
national programme aimed at ending mental health 
stigma. This is another important milestone in our 
organisation’s health and wellbeing journey and 
signals our enduring and sustained commitment to 
this cause.
Looking Ahead
We must always keep focussed on the future and on 
our continued progression as an organisation. My 
colleagues and I are honoured to work in a public 
service area where every day we have the possibility 
to make a difference in enhancing the health of 
people and animals. With that honour, comes a 
responsibility to ensure we both sustain and develop 
our regulatory approach. In line with this, we are 
now actively working with our Authority to prepare 
the next iteration of our strategic plan. This is a very 
exciting and motivating time for our organisation as 
we define what our key goals will be over the next five 
years. We look forward to the opportunities ahead 
and continued success in protecting and enhancing 
public and animal health. The investments we have 
made in our people and processes, and the value 
we place on collaboration with our stakeholders, will 
ensure that we deliver on our commitment to serve as 
a trusted and progressive health product regulator. 
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Planning for  
Brexit – Annual 
Update on  
Progress
The UK left the European Union on 
31 January 2020 on the basis of the 
Withdrawal Agreement which was agreed 
by the European Council on 17 October 
2019. The agreement includes a transition 
period until at least 31 December 2020. 
In March 2020, the EU and the UK began 
negotiations on a new future relationship 
agreement which, if agreed, is due to come 
into effect from 1 January 2021.
No matter what the final shape of Brexit looks 
like, the decision of the UK to leave the EU 
will result in changes to the European health 
products sector and regulatory network as a 
whole. The UK withdrawal from the EU has 
potentially significant implications for Ireland 
in particular given our shared marketplace 
and the fact that many health products are 
manufactured in or moved through the UK 
to get to Ireland. Consequently, the HPRA 
has been actively contributing to a whole-
of-Government response to Brexit, which 
includes a range of measures to ensure the 
continuity of supply of health products.
HPRA Response to Brexit
Once Article 50 was invoked by the UK on 
29 March 2017, the HPRA commenced our 
Brexit preparedness planning. The protection 
of public health by supporting the continued 
supply of health products after Brexit was 
identified as our key strategic objective while 
also optimising our role within the European 
regulatory network.
Adopting an organisation wide approach, an 
internal task force was established to inform 
internal and external planning as well as our 
communications and engagement activities. 
12
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As part of this approach, we developed the five key pillars to support delivery of our strategic 
objective and high level outputs: 
Key Brexit Pillars – Activities 
carried out in 2019 
Building on progress achieved during 2017 
and 2018, the following details the main 
activities and work streams delivered during 
2019 in respect of our five Brexit pillars:
1. Stakeholder Engagement and 
Communications
– There was continued implementation of 
our programme of communications and 
outreach including regular and sustained 
contact with individual manufacturers, 
industry, wholesalers and distributors, in 
addition to their representative bodies. 
In response to a number of deadlines 
in 2019, where the UK could have left 
without a deal, we contacted all MAHs to 
ensure Brexit preparedness, supply chain 
and regulatory compliance, and engaged 
with wholesalers to understand critical 
products, potential supply issues and 
capacity for “buffer” stocks.
– Our detailed Brexit guidance document 
and website content were both updated 
to reflect queries received from 
stakeholders and emerging information 
from the European Commission, the EMA 
and the HMA. Updates were also made 
to the medical devices and cosmetic 
products section of the HPRA website to 
highlight potential impacts of Brexit.
– We presented at a number of industry 
seminars on the impact of Brexit and held 
a HPRA stakeholder information day in 
February 2019. 
– There was regular staff communications 
in respect of Brexit planning.
2. Existing Work where the UK is Lead 
Member State
– We engaged with companies to facilitate 
the transfer of the RMS to the HPRA.
– We reviewed product exposure to the 





Stakeholder meetings, Q&As published, website content, one-to-one meetings with 
impacted stakeholders, presentations to industry meetings, media engagement.
Existing work where 
the UK is lead 
Member State
Committed to taking on all work where UK is the RMS and Ireland a CMS. Seeking 
newly available work under centralised system. Encouraging UK notified bodies to 
relocate to Ireland. Purpose: To maintain product on the market.
Future work to be 
allocated
Developing our capacity to bid for centralised and decentralised work to increase 
our European footprint and enhance our position as a leading EU regulator.
Leadership, 
Public Health and 
Advocacy
Ensuring the views of the Irish regulator are represented and understood at a 
European level. Proactively contributing to all EU Brexit meetings and engaging F2F 
with the Commission and the ENVI committee. 
Internal Capability Reviewing HPRA capacity to deliver on Brexit commitments. Staffing plan submitted 
to the Department of Health.
contacted companies to request that they 
transfer necessary regulatory functions to 
the EU.
– We contacted companies who have a 
large portfolio of products on the Irish 
market to understand any future barriers 
to supply and we responded to any 
potential supply issue identified.
– We provided updates in respect of joint 
labelling with the UK and met with other 
EU agencies to assess the possibility of 
multilingual labelling. 
– We concluded an agreement with the 
UK’s Veterinary Medicines Directorate for 
a work-sharing arrangement post Brexit.
3. Future Work to be Allocated
– 554 RMS transfers to Ireland were 
accepted in 2019 (502 in 2018); 285 for 
human medicines (346 in 2018) and 269 
for veterinary medicines (156 in 2018). 
– In respect of new outgoing MRP/DCP 
applications for human medicines, we led 
as RMS for the assessment of 17 cases/29 
products. In addition, we led as RMS 
for the assessment of 60 new MRP/DCP 
veterinary product applications including 
nine repeat use procedures. 
– We were appointed rapporteur / co 
rapporteur for 18 centralised human 
medicines while also being appointed co 
rapporteur for nine centralised veterinary 
products.
– We acted as co-ordinator for 102 EMA 
scientific advice procedures for human 
medicines. We were also co-ordinator 
(two) or joint co-ordinator (two) for four 
procedures in respect of veterinary 
medicines.
– There was an increase in the number 
of medical devices organisations 
establishing in Ireland as a result of 
Brexit, with 40 organisations registering 
as EU Authorised Representatives with 
the HPRA. There were also 3,565 medical 
devices registered during 2019.
4. Leadership / Public Health / Advocacy
– We participated in extensive planning 
with the Department of Health, the 
HSE and the FSAI for Brexit. This took 
the form of weekly meeting, both at 
a strategic and operational level. We 
participated in key work initiatives on 
managing medicines and medical devices 
availability in the event of no deal. 
– We participated in all Commission 
seminars and other EU meetings 
to advocate and promote greater 
understanding of the potential impact of 
Brexit for Ireland’s.
– We led discussions at an EU level for 
the acceptance of dual labelling and for 
a pragmatic approach to contingency 
planning. 
– There was also regular engagement 
with officials at the Department of 
Agriculture, Food and the Marine and the 
Department of Foreign Affairs and Trade.
– We engaged at a national level with the 
Revenue Commissioners with a view to 
minimising potential customs impact.
– We liaised with IDA Ireland, IBEC and 
industry representative bodies, and other 
stakeholders as appropriate.
5. Internal Capability
– Our Brexit planning includes due 
consideration of potential staffing 
requirements and we continued to work 
closely with the Department of Health on 
this matter. 
– We are committed to ensuring that we 
have sufficient staff levels to manage the 
implications of Brexit and throughout 
2019 we devoted expert staff resources 
to this important area through a 
combination of allocating existing staff as 
well as some new staff.  
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Contingency Planning for  
No-Deal Brexit
During the course of 2019, our Brexit planning 
was based on an initial no-deal outcome as 
of 29 March 2019, which was subsequently 
extended to 12 April, 31 October and 31 
January 2020. As a result, all our guidance 
and direction to industry stakeholders was 
based on a requirement for them to carry out 
all their regulatory changes in advance of the 
various deadlines. This involved confirming 
that their supply routes were capable of 
continuing supply to Ireland and reviewing 
stock levels to ensure that they had sufficient 
product available in the event of issues 
affecting entry points to Ireland as well as 
those in the UK and Europe. 
In 2019, the HPRA moved from operational 
planning to Brexit contingency planning under 
the following headings:
• Regulatory compliance of medicines and 
clinical trials authorised on the Irish market;
• Supply chain management and stock levels;
• Exempt medicinal products;
• Shortages protocol;
• Development of a list of essential 
medicines;
• Communications with stakeholders;
• Medical devices with UK CE marks;
• Veterinary medicines and engagement with 
the Department of Agriculture, Food and 
the Marine;
• Engagement within the European network.
As outlined, the withdrawal agreement 
provides for a transition period, which is due 
to expire on 31 December 2020. At time 
of publication, negotiations between the 
EU and the UK on a new future relationship 
agreement were ongoing. 
Much of the extensive preparatory work 
carried out by the HPRA and other 
stakeholders in 2019 will remain beneficial and 
relevant particularly if no trade deal, or only a 
limited trade deal, can be agreed. 
During the transition period, the UK remains 
subject to EU law and while it cannot act as a 
lead Member State and cannot be part of the 
EU institutions, it is still within the economic 
union and subject to medicines and medical 
devices legislation.
15
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Authorisation and Registration
• Prior to a new medicine being placed on the 
Irish market, it must be assessed and authorised 
(licensed) by the HPRA or by the European 
Medicines Agency (EMA) in conjunction with the 
European Commission. The assessment involves 
establishing that a medicine’s health benefits 
outweigh its known risks. Where this is the case, it 
may be granted a marketing authorisation.
 There are a number of routes through which a 
product can be authorised by the HPRA. These 
include the national procedure, the mutual 
recognition procedure (MRP) and the decentralised 
procedure (DCP). Both MRP and DCP involve 
the simultaneous submission of applications in a 
number of EU Member States. 
 The centralised route is co-ordinated by the EMA 
and results in an authorisation that is granted by the 
European Commission and is valid across Europe. 
The assessment is carried out by Member States 
appointed as lead assessor (rapporteur), joint lead 
assessor (co-rapporteur) and peer reviewer, with 
input also from all other Member States.
 During the year in review, the total number of new 
medicines authorised in Ireland was 433. The 2019 
figure incorporates:  
– 49 new national applications including 34 parallel 
import applications; 
– 52 applications made under the MRP and 194 
applications made under DCP. The HPRA acted as 
reference (lead) Member State for the assessment 
of 17 of these DCP applications;
– Five rapporteurships and 12 co-rapporteurships 
under the centralised route; 
– An additional 121 medicines authorised through 
the centralised route where the HPRA was neither 
rapporteur nor co-rapporteur.
• The EMA operates a scientific advice and protocol 
assistance procedure system to applicants on the 
appropriate tests and studies in the development 
of a medicine. This is designed to facilitate the 
development and availability of high quality, 
effective and acceptably safe medicines for the 
benefit of patients. During 2019, the HPRA acted as 
co-ordinator for 102 EMA scientific advice requests 
across a broad range of conditions.
 Our national scientific and regulatory advice 
procedure functions in a similar way and assists 
commercial and non-commercial entities making 
applications for clinical trial authorisation or 
marketing authorisations. This service complements 
advice that we provide on earlier stage product 
development through the Innovation Office. During 




The HPRA grants licences for medicines 
subject to a review of their safety, quality and 
effectiveness and continuously monitors their 
use once they become available on the Irish 
market. We also approve and monitor clinical 
trials, inspect and license manufacturing 
sites and wholesalers, and investigate 
activities associated with the illegal supply, 
manufacture or advertising of medicines.
• Participation in clinical trials can enable patients to 
benefit from new and promising therapies. During 
2019, we issued 88 new clinical trial applications. 
Of these, two applications were voluntary 
harmonisation procedures for clinical trials with the 
HPRA acting as lead Member State for these co-
ordinated work-sharing assessments of multinational 
clinical trials.   
• Reclassification of the legal status of medicines aims 
to increase the number of medicines available to 
patients without prescription where it is safe to do 
so. This year: 
– A medicine for the treatment of reflux symptoms 
(heartburn and acid regurgitation) was authorised 
for non-prescription, pharmacy-only sale.
– A medicine containing folic acid was authorised 
for sale in pharmacies and non-pharmacy outlets 
(general sale).  
• The HPRA publishes and maintains a list of 
interchangeable medicines to facilitate generic 
substitution by pharmacists and to allow for 
reference pricing by the Health Service Executive 
(HSE). By year-end, the interchangeable medicines 
list included 70 active substances.
• Medicine shortages have been an ongoing concern 
globally and in Ireland for some years. This year 
marked the first full year of operation of the 
Medicines Shortages Framework. This collaborative 
initiative brings together key players in the health 
sector with the aim of developing strategies to 
mitigate the effect of shortages in Ireland, thereby 
protecting patient health. Notable shortages 
addressed under the framework in 2019 included 
fentanyl injections (used in hospitals to prevent 
or relieve pain), total parenteral nutrition (used in 
hospitals for patients who have difficulty feeding) 
and ranitidine (used for conditions such as ulcers 
associated with stomach acid).
 Additionally, and in the context of Brexit, the HPRA 
has identified the use of multilingual labelling 
as a means of minimising the impact of the UK 
withdrawal on the availability of medicines in 
Ireland. Significant process was achieved during 
2019 in moving forward with this initiative including:
– The HPRA has taken the lead role within the 
Co-ordination group for Mutual recognition 
and Decentralised procedures – human (CMDh) 
and has developed a ‘Best Practice Guide on 
Multilingual Packaging’ which is now available on 
hma.eu website. As part of this process, the HPRA 
CMDh member consulted with interested parties 
who provided positive feedback on the guidance 
particularly in respect of products authorised 
through the national route. Extensive feedback on 
the associated challenges faced by stakeholders 
was also received and Ireland is leading a group 
of selected CMD(h) member states to address 
these challenges further.  
– In parallel, the Irish member of the Quality Review 
of Documents (QRD) Working Group at the EMA 
is actively contributing to revision of the existing 
’Compilation of QRD decisions on stylistic matters 
in product information’ guidance. This will further 
facilitate the development of multilingual labelling 
for products intended for the Irish market but 
authorised through the centralised procedure.
– The HPRA has updated its ‘Guide to Labels and 
Leaflets of Human Medicines’ to give detailed 
guidance to marketing authorisation holders 
(MAHs) on issues to consider when developing 
multilingual labelling. We have also confirmed 
that we are available to work with individual 
MAHs in developing multilingual labelling.
 A further mechanism utilised by the HPRA to aid 
continuity of supply to the market place in the event 
of a medicine shortage includes the granting of a 
temporary authorisation for a batch of a medicine 
known as a ‘batch-specific request’. In 2019, there 
were 240 requests received.
• We continued to monitor the numbers of 
unauthorised products notified to us through the 
exempt medicinal product scheme. One aspect 
of our approach to reducing the risks to patients 
is to actively seek new marketing authorisation 
applications for high-volume products currently 
being imported through this scheme. Three such 
authorisations were issued in 2019. 
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Safety and Quality
• Work continued in 2019 to manage the increased 
volume of reports and report reconciliation activities 
that that are a result of the introduction of changed 
reporting rules for the EU’s EudraVigilance database 
of adverse reactions in late 2017.
• Adverse reactions reports assist the HPRA, in co-
operation with pharmacovigilance professionals in 
Europe and further afield, to look for new types of 
reactions or changing trends in reporting. Reports 
submitted to the HPRA in many instances arise 
from concerns occurring during observation of an 
unexpected and / or unwanted event, in the context 
of use of a medicine. They also include known 
adverse reactions, such as those described in the 
product information. 
This year:
– 9,253 adverse reaction reports were received 
associated with the use of human medicines. This 
represents an 11% decrease in overall reporting 
rates compared with 2018. This decrease was 
solely in cases received from MAHs via the 
Eudravigilance database managed by the EMA, 
and can be attributed to increased stability in 
the operation of the pharmacovigilance system 
in 2019 after the change to reporting rules 
in November 2017. Clarification around the 
respective reporting roles and a decrease in 
inappropriate and duplicate reporting contributed 
to the stabilisation, although the latter still 
remains an issue. Overall, there was a 19% 
increase in direct reporting to the HPRA from 
healthcare professionals and members of the 
public.
Authorisation and registration: Key figures 2017 2018 2019
Classification queries / reviews 152 93 76
Scientific advice 
 Lead in EMA scientific advice:







Clinical trial applications 96 100 88
Voluntary Harmonisation Procedures (multinational clinical trials) 
 Lead







New medicines applications for marketing authorisations 
 National (including new parallel imports)
 Mutual recognition and decentralised RMS
 Mutual recognition and decentralised CMS













Traditional herbal medicinal products under the simplified registration 
scheme
4 4 2
Homeopathic medicines under the simplified/national rules schemes 2 3 3
Variations to marketing authorisations (Type IA, IB, II) 11,600 10,077 14,957
Articles 45 and 46 - Variations to Update Product Information 2 1 0
Renewals of marketing authorisations 248 597 291
Transfer of marketing authorisation holder 208 801 1,583
Manufacturers 111 127 135
Manufacturers of investigational medicinal products 52 63 69
Wholesalers 348 358 385













Brokers 9 8 8
Export certificates 1,375 1,319 1,367






































– Of the adverse reaction reports received by the 
HPRA in 2019, 90% were reported by MAHs, with 
a further 0.4% reported in the context of ongoing 
clinical trials. It is important to note that reports 
received by companies will have been initially 
notified to them by healthcare professionals, 
patients or consumers. 
– Medicines subject to additional monitoring 
accounted for 22% of the reports submitted.
– The breakdown of reports submitted directly 
by members of the public and healthcare 
professionals was as follows:





Healthcare professional - Other 4%
– The medicines most frequently included in 
reports to the HPRA accounted for 81% of the 
adverse reaction reports received in 2019 (see 
table below). It is important to note that the 
place of a medicine on this list cannot be taken 
as an indicator of safety or risk. The number of 
reports received cannot be used as a basis for 
determining the incidence of a reaction as neither 
the total number of reactions occurring, nor the 
number of patients using a medicine, is known.  










Anti-infective medicines, including 




Medicines for the treatment of Diabetes 365
Medicines for the treatment of Parkinson’s 
disease 325
Medicines regulating parathyroid 
hormone levels 262
Cardiovascular medicines, including 
antihypertensive, anti-arrhythmic and lipid 
lowering medicines
207
Pituitary and hypothalamic hormones and 
analogues 197
Other nervous system medicines 189
*  Please note that in some cases treatment may have involved 
more than one medicine from the groups listed.
– Of the new adverse reaction reports received by 
the HPRA in 2019, 159 patients were reported to 
have died while on treatment. The table (overleaf) 
outlines the medicines or class of medicines 
associated with the highest number of reports. In 
many of these cases, the patients had significant 
underlying illness and were treated with multiple 
medicines and/or surgery which may also have 
contributed to the outcome. In addition, many 
of these cases were influenced by disease 
progression or other complications unrelated to 
the medicine. The majority were associated with 
medicines subject to close monitoring, those used 
in the management of severe underlying medical 
conditions, in patient support programmes and 
special patient monitoring programmes.
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Antithrombotic medicines, including anti-
coagulant and anti-platelet medicines 18
Anti-infective medicines, including 
antibacterials, antimycotics, antivirals and 
immunoglobulins
7
Cardiovascular medicines, including 




Systemic corticosteroid medicines 5
Medicines for the treatment of diabetes 4
Medicines for the treatment of depression 4
Medicines for the treatment of 
gastrointestinal conditions 4
* Please note that in some cases treatment may have 
involved more than one medicine from the groups listed.
• The HPRA also plays a key role in monitoring 
the safety of medicines on the Irish market via 
our vigilance assessment and risk management 
activities. This incorporates our contribution to the 
work of the Pharmacovigilance Risk Assessment 
Committee (PRAC) at the EMA. During 2019, the 
HPRA:
– Continued our involvement in the work-sharing 
initiative for signal detection within the EU, acting 
as lead Member State for the monitoring of 70 
nationally-authorised active substances. Serving 
as PRAC rapporteur, we were also responsible for 
the further management of any signals detected 
in relation to 55 centrally authorised medicines 
(containing 40 active substances / combination of 
active substances).  
– Participated in the EU periodic safety update 
report (PSUR) single assessment procedure, 
contributing to the evaluation of 763 PSURs and 
leading the single EU assessment for 41 of these 
procedures.
– Participated as a concerned Member State in nine 
ongoing safety referrals, four of which reached a 
conclusion during the year.
– Contributed to the review of 334 risk 
management plans (newly approved or updated) 
submitted via national, mutual recognition, 
decentralised and centralised procedures. We 
also provided assessment input to 633 post-
authorisation safety procedures (safety study 
protocols, reports and other post authorisation 
safety-related measures).
• The HPRA continues to engage with multi-
stakeholder groups, including patient and 
clinical practice representatives, to facilitate 
clinical readiness at national level for new 
recommendations on the safe and rational use of 
medicines following major EU benefit-risk reviews. 
• Also during 2019, the HPRA commenced a research 
project, in collaboration with researchers from the 
RCSI, to assess the effectiveness of risk minimisation 
measures to prevent harms from teratogenic 
medicines. The project is funded through a Health 
Research Board Applied Partnership Award, which 
brings together the HPRA as knowledge user 
and the Royal College of Surgeons in Ireland as 
academic researcher. 
• The inspections programme focuses on ensuring 
compliance with relevant standards and legislation. 
This year, there were: 
– 96 good manufacturing practice (GMP) 
inspections at sites that produce human 
medicines or active substances.
– 135 good distribution practice (GDP) inspections 
at wholesalers and distributors;
– Six good clinical practice inspections at 
investigator or sponsor sites;
– Four pharmacovigilance inspections;
– One bioanalytical inspection of a contract 
research organisation;
– Four regulatory compliance inspections were 
conducted at the premises of marketing 
authorisation holders to determine the level of 
compliance with the legal requirements for the 
marketing and advertising of medicines. 
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• The risk-based sampling and analysis programme 
is part of our monitoring of the quality and safety 
of medicines on the Irish market or which are 
manufactured in Ireland for export. It involves the 
analytical testing of products and / or examination 
of their packaging and labelling. In 2019, 418 
samples were taken under the programme. This 
included:
– Examination of the packaging and labelling of 
126 medicines and other products available on 
the Irish market. Twenty-four non-compliances 
were identified including Braille-related issues, 
non-compliant packaging and labelling, and 
the absence of updated safety information. 
Appropriate follow-up actions were taken in each 
case.
– Analytical testing of 257 medicines and other 
samples of products for human use. With respect 
to non-enforcement samples, the majority were 
found to be compliant with their specifications. 
However, a number of out-of-specification results 
were also obtained. The most frequent of these 
related to nitrosamine impurity levels in sartan 
or ranitidine containing medicines being above 
the required limits. Again, appropriate follow-up 
actions were taken in each case.
• The quality defect and recall programme 
investigates, on a risk basis, reports of suspected 
quality defects in medicines and in their related 
active substances. It also co-ordinates recalls 
from the Irish market. Quality defects pertaining 
to 948 medicines for human use were reported 
or identified. The risk classifications that were 
assigned, along with the corresponding figures 
for the previous two years, are outlined in the 
accompanying table.          
Classification 2017 2018 2019
Critical quality defects 124 325 259
Major quality defects 196 280 291
Minor quality defects 327 308 375
Number of reports not justified 3 12 23
Total Number Quality Defects 650 925 948
 As in previous years, companies (47%), including 
manufacturers, distributors and/or authorisation 
holders, and other competent authorities (42%) 
were the primary sources of reports received. 
• In certain cases, it may be deemed necessary to 
withdraw, or recall, medicines from the Irish market 
in order to protect public health. During the year, 
125 medicine recalls occurred representing a 36% 
decrease when compared to 2018. Overall, the 
most common causes of recalls were:
Cause of Recall Number of 
Recalls
Lack of sterility assurance 32
Contamination issues 29
Erroneous distribution activities 19
Stability issues 7
SPC / Printed artwork component issue 8
Non-compliance with specifications 5
• The HPRA monitors the sale of certain consumer 
health products in outlets such as grocery 
shops, health food shops and, where necessary, 
pharmacies. During 2019, 11 cases were 
investigated, some of which involved multiple 
products. Of these:
– nine cases related to the sale of medicines 
that did not carry a valid registration number 
or authorisation number for the Irish market, 
resulting in 18 medicines being removed from 
sale and necessary follow-up actions being taken; 
– two cases related to the classification status of the 
products. 
 In addition, 80 queries linked to the sale of health 
products in Ireland were addressed.
• The advertising compliance programme monitors 
and reviews advertising and promotion activities 
carried out by the industry in relation to human 
medicines for compliance with the legislation. In 
total, 414 advertisements were reviewed, and non-
compliances, including both major and minor issues, 
were identified in 145 of these. In addition, one 
critical deficiency, two major deficiencies and several 
other (i.e. minor) deficiencies related to advertising 
activities were identified during inspections of 
marketing authorisation holders. In all cases, we 
oversaw the necessary corrective and/or preventative 
actions, where relevant. Seventeen complaints linked 
to the advertising of medicinal products were also 
received while 41 advertisements were recalled. A 
number of recalls were linked to complaints received. 
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• Under our enforcement programme:
– The HPRA detained 1,018,678 dosage units 
(including tablets, capsules and vials) of falsified 
and other illegal medicines in 2019, compared 
to 619,213 units in 2018. The products detained 
included sedatives (34%), erectile dysfunction 
medicines (28%) and anabolic steroids (12%). 
There were 6,167 enforcement cases initiated, 
compared to 4,532 in the previous year;
– Several HPRA operations took place in 
conjunction with An Garda Síochána and 
Revenue’s Customs Service. These operations 
resulted in several large detentions, including the 
detention of over 60,000 capsules, tablets and 
vials labelled as anabolic steroids and destined 
for sale in the EU, and, in another investigation, 
40,000 units of falsified diazepam tablets; 
– We initiated eight prosecution cases and issued 
nine voluntary formal cautions. Prosecutions are 
taken where the HPRA considers that there is a 
significant risk to public health or where there are 
persistent non-compliances. The prosecutions 
related to the unauthorised supply of prescription 
medicines, including falsified anabolic steroids, 
erectile dysfunction products and melanotan 2 
(tanning injection) containing medicines. We also 
supported prosecutions brought by the Director 
of Public Prosecutions in relation to the illegal 
supply of medicines;
– The Interpol-coordinated Operation Pangea XII 
was a year-long operation designed to enhance 
worldwide cooperation between health products 
regulators and other government agencies. The 
continued joint agency cooperation between the 
HPRA, Revenue’s Customs Service and An Garda 
Síóchána was reflected in the HPRA detention 
figures for 2019. In addition, the monitoring of 
websites, online marketplace advertisements and 
social media sites throughout the year resulted in 
the shutdown of 40 sites.  
Legislation and Regulation
• The new Clinical Trial Legislation, Regulation 
EU No 536/2014, is provisionally planned to be 
implemented during 2021, when the development 
of the Clinical Trial Information System (CTIS) has 
been completed by the EMA. 
 The following national activities were progressed 
during 2019:
– We continued to engage with the Department 
of Health regarding the implementation of the 
Regulation and the development of national 
legislation; 
– We continued to offer a pilot project for 
simultaneous submission of applications to both 
the HPRA and ethics committee, which enables 
preparation for implementation of the Regulation. 
Guidance and templates for sponsors are 
available on our website;
– We actively participated in the European 
voluntary harmonisation project, which is similar 
to the approval process for clinical trials under the 
planned new legislation (see page 17).
• Since 9 February 2019, under the Falsified 
Medicines Directive, the outer packs of prescription 
medicines must carry safety features in the form of 
an anti-tamper device and a barcode containing 
unique identifiers, including a serial number to 
allow verification of the authenticity of the packs. In 
2019:
– Preparations for the national implementation 
and introduction of these measures intensified. 
We worked with the Irish Medicines Verification 
Organisation (IMVO), which was responsible for 
establishing and managing the repository and 
software systems; 
– We contributed to a National Oversight Steering 
group of stakeholders which met regularly 
to monitor progress on implementation both 
nationally and across the EU;
– The EU working group on supervision of the 
national repositories of unique identifiers, led by 
the HPRA, continued to work through its plan for 
the project. 
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Stakeholders and Partners
• In January, the HPRA’s Chief Executive, Deputy 
Chief Executive and Director of Quality, Scientific 
Affairs and Communications, appeared before 
the Joint Committee on Health to address 
the implications of Brexit for the health sector. 
Following presentations from the Department of 
Health and the HSE, the HPRA responded to a 
number of queries linked to our regulatory role, 
with a particular focus on the potential impact of 
Brexit on medicines supply. 
 In September, the HPRA appeared before the 
Committee once more to discuss the same topic. 
The HPRA’s Chief Executive, Deputy Chief Executive 
and Scientific Affairs Manager attended again with 
representatives from the Department of Health and 
the HSE. On this occasion, the HPRA presented 
a detailed update on the extensive regulatory 
planning and stakeholder engagement that was 
intensifying in preparation for the potential worst-
case scenario associated with a disorderly Brexit. 
The Committee was informed of the HPRA’s 
commitment to protect the supply of medicines to 
Irish patients and healthcare professionals to the 
fullest extent possible, The HPRA also provided 
responses to a number of queries from the 
Committee members.
• As in recent years, the HPRA delivered a 
programme of presentations and talks at 
external stakeholder events such as meetings, 
seminars, conferences and training courses. 
Such presentations provide stakeholders such 
as healthcare professionals and regulatory 
professionals with access to relevant, up-to-
date information. In addition, a programme of 
presentations was delivered to undergraduate and 
postgraduate students studying courses related to 
the role of the HPRA. A full list of all presentations 
delivered during 2019 relevant to human medicines 
is provided in Appendix 2.
• Publications and Information 
– The Drug Safety Newsletter provides important 
safety information to healthcare professionals 
with hyperlinks to product information and other 
relevant documents on the HPRA and EMA 
websites. Four issues of the newsletter were 
published and distributed to registered healthcare 
professionals, all of which are accessible from 
the HPRA website. A full index of topics covered 
during the past year is included in Appendix 3.
– Risk communications: 
 During 2019, 112 new or updated educational 
materials were approved by the HPRA in 
addition to 28 direct healthcare professional 
communications. 
 The PRAC monthly agendas, minutes, meeting 
highlights, notifications of safety reviews 
and signals were also made available via our 
website.
– There were 23 articles provided for inclusion in 
the monthly MIMS (Ireland) publication in addition 
to two articles for the Irish Medicines Formulary. 
The full list of topics covered in these articles is 
included in Appendix 3. 
– The Medicinal Products Newsletter provides 
regulatory news and updates for those working in 
the pharmaceutical industry. Three editions were 
published on our website in 2019 and are available 
to download from the ‘Publications’ section. 
– HPRA guidance documents provide stakeholders, 
primarily from the industry sectors we regulate, 
with advice and direction in respect of legislation 
and regulatory requirements. A number of existing 
guidance documents were updated during 2019 
and are available to download from our website. 
• HPRA information seminars and training events 
provide regulatory guidance and updates to a 
range of stakeholders. Our programme of events 
in 2019 included an information day on Brexit in 
February attended by over 300 delegates. We also 
hosted two significant international meetings linked 
to our enforcement activities. The first, organised in 
cooperation with Interpol over three days in March, 
considered Operation Pangea XI and combating 
the sale of illicit medicines online. The second, 
a weeklong event held at the end of May, was a 
meeting of Permanent Forum on International 
Pharmaceutical Crime (PFIPC). These two meetings 
together attracted more than 150 delegates.
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Authorisation and Registration
• The HPRA is focused on ensuring effective and 
consistent designation and oversight of notified 
bodies at national and European level. In 2019, we:
– Assessed applications from organisations seeking 
to be designated as notified bodies in Ireland 
under the new EU Regulations on medical 
devices; 
– Continued our schedule of oversight of the 
notified body in Ireland based on ongoing 
assessment, surveillance and observed audits;
– Provided expert assessors to participate in three 
EU joint assessments of notified bodies based in 
other European countries; 
– Continued to support development of EU 
coordination of notified body designation and 
oversight through participation in the EU Notified 
Body Operations Group (NBOG) and the Medical 
Device Coordination Group (MDCG).
 
• Supporting innovation and research of new 
technologies is a key strategic priority for the HPRA 
medical devices team. In 2019, this involved:
– The review of applications to conduct clinical 
investigations of medical devices in Ireland. The 
number of clinical investigations decreased with 
five new applications and ten amendments to 
ongoing investigations. The HPRA anticipates 
that these numbers will increase when the new EU 
Regulations are implemented; 
– The HPRA continues to focus on this area to 
ensure regulatory requirements and processes are 
clear and accessible to potential applicants;
– Encouraging engagement during product 
development and innovation of medical 
technologies. We met with 19 groups of 
innovators to discuss potential clinical 
investigation applications in 2019;
– Supporting the work of the HPRA Innovation 
Office on medical devices queries received;
– Presenting and participating in innovation 
sessions at a variety of conferences and 




As the national competent authority for 
medical devices, the HPRA carries out a 
range of registration, surveillance, monitoring 
and compliance activities. Our aim is to 
ensure that these health products perform as 
intended and do not compromise the health 
and safety of the patient or the person using 
them.
• Manufacturers of certain medical devices and 
in-vitro diagnostics are required to register with 
the HPRA. In 2019, the HPRA registered 99 new 
organisations manufacturing these products in 
Ireland. A total of 6,037 medical devices were also 
registered. This represented increased registrations 
when compared to previous years, some of which 
is attributable to the UK’s exit from the European 
Union. 
Safety and Quality
• We continue to develop and reinforce our market 
surveillance activities, with particular emphasis on 
proactive rather than reactive actions. Of note in 
2019:
– We utilised a lifecycle market surveillance strategy 
and planning mechanism to ensure continued 
safety and performance of devices throughout 
their lifetime; 
– We led or participated in various elements of 
both technical work packages of the EU Joint 
Action on Market Surveillance (JAMS) of medical 
devices initiative which is funded by the European 
Health Programme and aims to develop market 
surveillance activities; 
– A total of nine COEN notices were sent to the 
European network relating to medical device 
compliance concerns;
– One information notice was published in relation 
to medical devices used during electrosurgery; 
– There were 1,645 market surveillance cases 
undertaken in 2019, a slight increase compared to 
2018. Key areas of focus for market surveillance 
review included transvaginal mesh implant 
devices and breast implant-associated anaplastic 
































• We continued to focus our vigilance activities 
during 2019 on the areas of user reporting and 
dissemination of HPRA medical device safety 
communications. This included:
– The receipt and assessment of 2,295 medical 
device vigilance cases, similar to numbers 
received in 2018. Of the 1,105 incident reports 
notified to the HPRA, 13% came from users of 
medical devices. Manufacturers accounted for 
60% of all reports received in 2019 while 32% 
came from other competent authorities; 
– There were 409 field safety corrective actions 
(FSCA) associated with the national market 
including 128 product removals conducted in 
Ireland during 2019; 
– We issued 84 national competent authority 
reports, eight notified body forms and four 
vigilance enquiry forms;
– We also issued 33 safety notices in relation to 
medical device issues and 63 direct to healthcare 
professional communications; 
– Surgical devices, orthopaedic devices, implants 
and infusion devices accounted for 52% of the 
total vigilance reports. Reports continue to be 
received relating to in vitro diagnostic devices 
in the area of clinical biochemistry and medical 
devices in the areas of diagnostic imaging and 
vital signs monitoring. During the year, we also 
continued development work on signal detection 
of medical device issues.
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• As part of its market surveillance activities, the 
HPRA undertakes proactive and ‘for-cause’ audits 
of manufacturers, notified bodies and authorised 
representatives with the objective of monitoring 
compliance of devices emanating from Irish based 
organisations. During 2019, nine audits were 
performed at notified bodies, medical device 
manufacturers and authorised representative 
facilities, of which:
– one was a for cause audit;
– eight were based on proactive market surveillance 
projects and notified body surveillance/
assessment.
 In addition, there were three good distribution 
practice (GDP) inspections in respect of medical 
devices.
Legislation and Regulation
• The two new European Regulations on medical 
devices will become fully applicable in 2020. We 
continued our work during 2019 to help ensure 
an effective and timely implementation of these 
EU Device Regulations (EUDR) at national and 
European level. This included:
– Implementing a HPRA programme plan for 
development of appropriate resources, process 
and systems to meet our obligations under the 
new EUDR;
– Preparing detailed information relating to the new 
requirements with respect to the need for national 
legislation, the timelines and impact on existing 
national legislation;
– Contributing to the European Commission’s 
development of the secondary legislation 
involving implementing and delegating acts; 
– Participating in the new EU Medical Device 
Coordination Group (MDCG). Chaired by the 
EU Commission, this group is responsible for 
the overall coordination and governance of the 
regulatory system;
– Participating in the EU Working Groups tasked 
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 We continued to engage with the Department of 
Health throughout 2019 on policy and legislative 
issues arising from implementation of the new EU 
Regulations. At national level, we further developed 
our national fee-based funding model for medical 
devices to recover costs associated with our 
medical device activities. The model was revised in 
2019 to streamline the approach and address some 
of the comments and feedback received following 
its initial introduction.
• The HPRA continues to play a significant role 
in the development of EU regulatory systems 
and mechanisms to promote co-ordination, co-
operation and consistency. In 2019, this included:
– Re-election to the Executive Group of the 
Competent Authorities for Medical Devices 
(CAMD) network. This group has successfully 
worked in partnership with the EU Commission 
over the last number of years to develop the 
regulatory system in Europe;
– Participation in the CAMD’s Implementation Task 
Force (ITF) and Transition Subgroup (TSG) which 
aim to improve co-ordination and consistency 
of implementation of the new EU Regulations 
and published guidance on what it means to be 
compliant by May 2020;
– Continuing to lead the work of the clinical 
investigation and evaluation working group 
(CIEWG), acting as the co-chair along with the EU 
Commission.
• We continued to participate actively in initiatives 
to promote regulatory convergence and 
harmonisation of medical devices globally through 
the International Medical Device Regulators Forum 
(IMDRF). This involved:
– Participation in the IMDRF Management 
Committee as part of the European delegation 
(along with the EU Commission, France and 
Germany); 
– Continuing to act as the IMDRF secretariat for 
the National Competent Authority Report (NCAR) 
Exchange programme. We also participated in 
a number of different IMDRF working groups 
including the group on Medical Device Single 
Audit Programme (MDSAP);
– Contributing to discussions and development of 
the Medical Device Single Review Programme, 
which relates to product review;
– Contributing to briefings for the EU Commission 
for the purposes of the MDSAP Regulatory 
Authority Committee discussions and also 
encouraging discussions at EU level to further 
Europe’s future engagement in the programme.
 
Stakeholders and Partners
• Our work to further developing our stakeholder 
engagement and communication with medical 
devices stakeholders continued throughout 2019. 
This included the promotion of direct reporting 
of incidents and medical devices issues by 
device users and members of the public. We also 
continued our engagement with health services and 
healthcare professionals to encourage reporting 
and raise awareness of the roles and activities of 
the HPRA. We again promoted the adoption and 
communication of the HPRA step-by-step guide 
to user reporting which is targeted at healthcare 
providers. 
• The HPRA undertook a number of communication 
initiatives to raise awareness of the impact and 
requirements arising from the new EUDR. During 
2019, we:
– Supported the TOPRA 2019 symposium on 
medical devices for manufacturers in Dublin. The 
event, which included a number of presentations 
from HPRA staff members, was attended by 
around 140 participants; 
– Continued to update the HPRA website and 
social media channels to provide information and 
guidance regarding EUDR; 
– Provided briefings, advice and workshops on 
the new Regulations to a range of different 
stakeholders including notified bodies and 
distributors. 
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• Throughout the year, we engaged in ongoing 
strategic, operational and communication 
initiatives on a bilateral and multilateral basis 
with European and international authorities, and 
the EU Commission. We also further developed 
our bilateral partnerships with a number of 
those authorities. In addition, we participated in 
operational and strategic discussions on developing 
cooperation between the CAMD and the Heads of 
Medicines Agencies (HMA) networks.
• The HPRA continues to deliver a programme of 
presentations and talks to a range of external 
stakeholders. A full list of all presentations related 
to the regulation of medical devices that were 
delivered during 2019 is provided in Appendix 2.
Medical devices: Key figures 2017 2018 2019
Lead Competent Authority role 
on specific vigilance issues
89 74 84






Field safety notices uploaded 519 475 461
Medical device safety notices 44 39 33




NCARs managed as IMDRF 
NCAR secretariat
8 8 8
COEN reports (market 
surveillance and vigilance) to 
EU network
44 38 9
Medical device information 
notices
5 2 1
Market surveillance cases 
(unadjusted)
411 353 263
Notifications relating to notified 
body certificates
844 1,174 1,305




Medical device free sale 
certificates
2,371 2,581 2,710
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Authorisation and Registration
The authorisation of blood establishments, tissue 
establishments and organ procurement organisations 
/ transplantation centres permits those facilities to 
carry out specified activities. The total number of 
authorisations in place at year-end for the past five 




2015 2016 2017 2018 2019
Blood 
establishments
3 3 3 3 3
Tissue 
establishments




4 4 4 4 4
Safety and Quality
• Following collaboration with the National 
Haemovigilance Office (NHO), we submitted an 
annual report of serious adverse reactions and 
events to the EU Commission during 2019. The 
report reflected information received by the NHO 
in 2018 and included information on 46 serious 
adverse reactions and 128 serious adverse events 
that met the mandatory legislative reporting 
requirements. 
• We also submitted an annual report on serious 
adverse reactions and events associated with tissues 
and cells to the EU Commission during 2019. The 
report reflected information received in 2018 and 
consisted of some 32 reports, 27 of which met the 
legislative reporting requirements, including three 
serious adverse reactions and 24 serious adverse 
events.
• Updates to the common approach for defining 
reportable serious adverse reactions and events and 
other vigilance activities in Europe are continuing 
under the SoHO Vigilance Expert Sub-Group (VES) 
at which the HPRA is actively participating. During 
2019, the remit of this group was extended to 





The HPRA is responsible for monitoring 
the safety and quality of blood and blood 
components and of tissues and cells. Along 
with the HSE, we are joint Competent 
Authority for organs intended for 
transplantation.
• We continued to liaise with the HSE lead and 
colleagues from Organ Donation and Transplant 
Ireland (ODTI) in relation to our respective roles 
under EU and national legislation on the Quality 
and Safety of Human Organs intended for 
Transplantation. During the past year, this included:
– The exchange of relevant information on serious 
adverse reactions and events. In 2019, the 
HPRA received twelve reports of serious adverse 
reactions and events associated with organ 
donation / transplantation;
– Updates to the organ report form;
– Contribution to the review of the ‘Framework 
for the Quality and Safety of Human Organs 
Intended for Transplantation’.
• We inspect relevant establishments, organisations 
and centres to monitor compliance with applicable 
national and EU legislation and guidelines on 
the quality and safety of blood, blood products, 
tissues and cells, and human organs intended for 
transplantation. Our inspection programme in 2019 
included:
– 24 tissue establishment inspections of which two 
were non-routine; and
– Seven routine inspections of blood 
establishments.
Legislation and Regulation
• As part of our ongoing contribution to the 
preparation of relevant legislation, we provided 
feedback to the Department of Health on draft 
statutory instruments (SIs) for transposition of EU 
Directives on coding and import of human tissues 
and cells, which were signed early in the year, and 
on their implementation. 
• In relation to assisted human reproduction, 
we engaged with the Department of Health 
on development of related legislation. We 
also continued to engage in respect of the 
commencement of parts 2 and 3 of the Children 
and Family Relationships Act 2015. A related 
Commencement Order was signed that will come 
into effect on 4 May 2020.
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Authorisation and Registration
• There are a number of procedures through which a 
veterinary medicine can be authorised by the HPRA. 
These include the national procedure, the mutual 
recognition procedure (MRP) and the decentralised 
procedure (DCP). The following applications were 
issued by the HPRA during 2019: 
– Eleven new national applications; 
– 86 new applications made under the DCP; 
– Thirty new applications made under the MRP. 
 We acted as reference (lead) Member State for the 
assessment of 13 of the MRPs and 38 of the DCPs. 
We also led a further nine applications as RMS 
under the repeat use procedure.
 The centralised route administered by the EMA is 
another mechanism whereby veterinary medicines 
can be authorised for supply in Ireland. HPRA 
experts acted as rapporteur or co-rapporteur in 
respect of 24 new veterinary medicines. 
 Based on the figures presented above, the HPRA 
was the leading national competent authority in the 
EU for outgoing work during 2019.
 Additionally, by year-end, there was a record total 
of more than 1,850 veterinary medicines authorised 
in Ireland.
• During 2019, HPRA experts acted as co-ordinator 
(two) or joint co-ordinator (two) for four EMA 
scientific advice procedures.
• Concerning Brexit planning and preparation (see 
also pages 12 to 15), we focused on the HPRA’s 
key strategic aim of protecting the availability of 
veterinary medicines on the Irish market while also 
optimising our role within the European regulatory 
network. During the past year, this included:
– Changes to transfer procedures made to mitigate 
against Brexit related shortages. There was a total 
of 269 RMS transfers to Ireland;
– Engagement with industry to identify potentially 
vulnerable products;
– Recruitment and training of additional staff in 
response to anticipated increase in workload;
– Discussion with the UK’s Veterinary Medicines 
Directorate for a possible work-sharing 
arrangement post Brexit. 
• Medicine shortages continue to be a challenge for 
many veterinary practitioners tasked with treating 




Our role is to grant licences for veterinary 
medicines subject to a review of their safety, 
quality and effectiveness. We continuously 
monitor the use of the products concerned 
in animals once they become available on the 
market in addition to authorising clinical field 
trials and inspecting / licensing  
manufacturing sites.
availability can arise from a number of issues and 
different solutions are needed depending on the 
issues involved. In 2019:
– We conducted planned quarterly reviews of AR18 
and AR16 lists which provide details of veterinary 
medicines that have been granted special import 
licences by the Department of Agriculture, Food 
and the Marine. The HPRA strategy is to review 
the lists to identify required medicines and 
to encourage an applicant to seek a standard 
marketing authorisation where practicable;
– Carried out gap analysis and prioritised 
applications linked to shortages;  
– Meetings were held with the Department of 
Agriculture, Food and the Marine to discuss 
shortages related issues including the need to 
develop an inter-departmental process in respect 
of potential shortages arising from Brexit; 
– Communicated and met with applicants regarding 
transfer of RMS to Ireland. We also revised the 
relevant procedure and established a register of 
products for transfer;
– We worked closely with EU competent authorities 
to enable the use of common packs. 
Authorisation and registration: 
Key figures 2017 2018 2019
Classification enquiries 11 26 12
Clinical trials 2 10 4
New centralised as (co-)
rapporteur 16 3 24
New MR/DCP as RMS 30 34 38
New MR/DCP as CMS 44 57 48
New homeopathic applications 3 0 3
New national applications 8 11 6
Renewals, national and MR 108 148 87
Variations, national and MR 1,366 1,820 2,153
Manufacturers of veterinary 
medicines 20 23 24
Export certificates 111 109 125
Safety and Quality
• The operation of a national pharmacovigilance 
system for veterinary medicines is dependent 
on the submission of reports by veterinarians, 
pharmacists, licensed merchants and others 
involved in dispensing or using the medicines 
concerned. These reports may be submitted either 
directly to the HPRA or to the companies marketing 
the medicines. The companies, in turn, must relay 
the data to the HPRA.
 Over the course of 2019, we received 347 national 
reports of suspected adverse events to veterinary 
medicines with the vast majority of reports, as 





























• We processed 1,189 periodic safety update reports 
(PSURs) which incorporated the assessment of 
individual medicines on the market in Ireland as 
well as a work-sharing initiative where we led, 
or contributed to, the assessment of a class of 
veterinary medicines for the European Union. . 
• Containment of the development of antimicrobial 
resistance (AMR) is essential for public and animal 
health. Our work in this area includes the collection 
of annual information on the sale of veterinary 
antibiotics from each marketing authorisation 
holder. This information, which is included in the 
European Surveillance of Veterinary Antimicrobial 
Consumption (ESVAC), is important as it allows us 
to benchmark our usage rate against those of our 
European neighbours and to follow any developing 
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trends. The data show that due to a variety of 
factors there are significant fluctuations in sales 
annually and, consequently, that a clear trend is not 
identifiable.   
Veterinary antibiotic 
use 2014 2015 2016 2017 2018
Tonnes sold 89.4 96.9 103.4 99.7 99.4
 
 Additionally in 2019, we collaborated with the 
Department of Agriculture, Food and the Marine 
to support the development of a database for 
antimicrobial consumption as per ‘Ireland’s National 
Action Plan on Antimicrobial Resistance 2017-2020’. 
• The analytical testing of products is a key 
component of the HPRA’s risk based sampling and 
analysis programme. Eight samples of veterinary 
medicines were taken under the programme and 
all were subjected to laboratory testing. In respect 
of all completed tests, samples were found to be 
compliant with their specifications. 
• We investigate, on a risk basis, reports of suspected 
quality defects in medicines and active substances, 
and co-ordinate subsequent recalls from the Irish 
market where necessary. There were 68 quality 
defects pertaining to medicines for veterinary 
use reported or identified. The risk classifications 
that were assigned, along with the corresponding 
figures for the previous two years, are outlined in 
the accompanying table.           
Classification 2017 2018 2019
Critical quality defects 5 26 10
Major quality defects 13 43 19
Minor quality defects 30 56 38
Number of reports not justified 0 0 1
Total Number Quality Defects 48 125 68
 Companies (38%), including manufacturers, 
distributors and/or authorisation holders, and other 
competent authorities (62%) were the sources of the 
reports received.  
 
 In certain cases, in order to protect animal and/or 
public health, it is deemed necessary to withdraw, 
or recall, a veterinary medicine from the Irish 
market. Seven recalls of medicines occurred which 
was one more than in 2018. Of these, two were due 
to a lack of sterility assurance.
• Our inspections programme focuses on ensuring 
compliance with relevant standards and legislation. 
In 2019, there were 14 good manufacturing practice 
(GMP) inspections of sites that manufacture / test 
veterinary medicines. 
Legislation and Regulation
• The new veterinary regulation came into effect on 
28 January 2019 and will be applied from 2022. 
During 2019, we continued to meet and engage 
with the Department of Agriculture, Food and the 
Marine in respect of the preparations needed to 
support the new Regulation (Regulation 2019/6). In 
addition, we published an initial assessment of the 
impact of the medicines Regulation on veterinary 
practice in the Veterinary Ireland Journal. Planning 
in respect of the implications of the legislation on 
HPRA procedures is ongoing. 
• We continued to monitor developments regarding 
the judicial review proceedings that contended that 
the labelling and packaging of veterinary medicines 
should be in both the Irish and English languages. 
It is noted that the matter has been referred to the 
European Court of Justice. 
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Stakeholders and Partners
• As part of our ongoing stakeholder engagement, in 
2019 we:
– Engaged in a consultation with stakeholders 
regarding the method of supply of antiparasitic 
veterinary medicinal products that are intended 
for food-producing animals, and produced a 
report on this topic;
– Met with key interested parties (veterinary and 
farming organisations) to discuss availability issues 
and possible solutions. 
   
• Throughout 2019, we continued our involvement 
across the EU regulatory network, which includes 
active participation at the EMA and the HMA. 
• As in recent years, we delivered a programme 
of presentations to veterinarian students and 
veterinary nursing students on the role of the HPRA 
and the promotion of veterinary pharmacovigilance. 
We also presented at a number of industry 
stakeholder events. A full list of all presentations 
delivered during 2019 is provided in Appendix 2. 
• Our Medicinal Products Newsletter provides 
updates for those working in the veterinary 
medicines sector on Irish and European legislation, 
new / revised HPRA regulatory publications and 
stakeholder events such as information days. Three 
editions were published on our website in 2019 and 
are available to download from the ‘Publications’ 
section.
• We also contributed a number of articles to the 
Veterinary Ireland Journal and the It’s Your Field 
publication. Details are included in Appendix 3.
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Authorisation and Registration
• The HPRA carries out evaluations of applications 
for the authorisation of research establishments and 
projects in addition to evaluating applications from 
individuals to allow them to manage projects or to 
conduct procedures or euthanasia of animals. 
 As shown in the accompanying table, there 
was a decrease in the total number of projects 
authorised in 2019. In addition to the new individual 
authorisations issued during the year, there were 







































Scientific Animal  
Protection
The HPRA is the competent authority in 
Ireland responsible for the implementation 
of EU legislation (Directive 2010/63/EU) for 
the protection of animals used for scientific 
purposes.
• In June, we published the sixth annual statistical 
report on the use of animals for scientific purposes 
in Ireland. The HPRA is required to collect and make 
publicly available, on an annual basis, statistical 
information on the use of animals in procedures, 
including information on the actual severity of the 
procedures.









• During 2019, there were 31 inspections completed 
to monitor animal welfare standards and compliance 
with legislation, of which 32% were unannounced. 
This total incorporated one establishment 
authorisation inspection, one establishment renewal 
inspection and 29 compliance inspections.
 Of the 31 non-compliances recorded under 
the annual inspection programme, 26% were 
self-reported to the HPRA by personnel at the 
authorised establishment with the remainder 
detected on inspection or during other HPRA 
activities. Non-compliances are categorised as Type 
1, Type 2 and Type 3, with Type 1 being the most 
serious and Type 3 being more minor in nature. In 
2019, 6% of non-compliances were Type 1 (and 
these were all self-reported), 55% were Type 2 
and 39% were Type 3. The most common non-
compliances recorded related to (i) breaches of 
project authorisations, (ii) breaches of individual 
authorisations and (iii) issues with the control of 
relative humidity in animal holding rooms.    
Stakeholders and Partners
• In 2019, we published and disseminated four 
‘Regulatory Updates’ to provide stakeholders 
with the latest news and guidance from the HPRA 
including information on best practices in respect of 
the 3Rs and compliance with the legislation.
• We delivered a number of Laboratory Animal 
Science and Training (LAST) lectures in relation to 
the legislative and regulatory aspects of scientific 
animal protection. In June, we delivered a lecture 
at a meeting of the Irish designated veterinarians 
group, in relation to the responsibilities of the 
designated veterinarian under the scientific animal 
protection legislation.  
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Authorisation and Registration
• Import, export and holding of controlled drugs (for 
legitimate purposes) are subject to licensing. The 
Department of Health is the licensing authority 
while the HPRA handles the administrative aspects 
of the application and licensing process. Licensing 
activity consists primarily of export and import 
licences, and letters of no objection. Data for the 
past five years are outlined in the accompanying 
graph.
• The HPRA is the licensing authority for precursor 
chemicals. These are subject to different licensing 
requirements, dependant on specific categories. 




2015 2016 2017 2018 2019
Total 32 16 23 23 13
• The HPRA processes, on behalf of the Department 
of Health, applications for licences to cultivate 
hemp. A cultivation licence is valid for a period of 
one year from the date it is granted. The below 
table shows the number of licences issued during 
the past four years.
Hemp Cultivation 
Licensing Activity
2016 2017 2018 2019
Total 7 16 24 74
Safety and Quality
• The HPRA carries out inspections of manufacturers 
and distributors of controlled drugs, as well as 
some other operators, as necessary, to monitor 
compliance with the relevant requirements. We 
conducted 19 inspections linked to the possession 
and/or supply of controlled drugs. Operators were 
informed of any non-compliances identified and 



































• Throughout 2019, the HPRA provided support to 
the Department of Health in the establishment 
of the Medical Cannabis Access Programme. In 
June, Minister Harris signed the Misuse of Drugs 
(Prescription and Control of Supply of Cannabis 
for Medical Use) Regulations 2019 (S.I No. 262 
of 2019), the legislation required to underpin the 
programme. This allowed for commencement of 
the first stage, which was for potential suppliers 
to apply to have their cannabis products assessed 
for suitability for supply under the programme. 
Over the second half of 2019, a small number of 
applications from commercial suppliers seeking to 
have their products included were considered by 
the HPRA. From these applications, three cannabis 
products were considered to meet the specified 
requirements and were added to the programme. 
 When the programme is fully operational, 
consultants on the specialist medical register will be 
able to prescribe a cannabis-based treatment for 
patients with any of three specified conditions: 
– Spasticity associated with multiple sclerosis 
resistant to all standard therapies and 
interventions; 
– Intractable nausea and vomiting associated with 
chemotherapy, despite the use of standard anti-
emetic regimes; 
– Severe, refractory epilepsy that has failed to 
respond to standard anticonvulsant medications. 
Further information is available on the Department 
of Health website.  
Stakeholders and Partners
• In June, we were invited to present at the Premier 
Irish Industrial Hemp Conference organised by 
GlasTeo and Teagasc on the application process 
for licences to cultivate hemp. The workshop was 
attended by external stakeholders with an interest 
in hemp cultivation. 
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Authorisation and Registration
• We issued 165 cosmetics free sale certificates, 
which were requested by companies intending to 
export products to non-European Economic Area 
countries. 
Safety and Quality
• As part of proactive market surveillance activities, 
we conducted one inspection of a cosmetic 
distributor and initiated one Product Information 
File (PIF) review to assess compliance with the 
Cosmetics Regulation. We informed distributors 
and manufacturers of any non-compliances 
identified and requested implementation of 
corrective actions.
• Our reactive market surveillance includes 
investigation of quality-related complaints 
(compliance cases), reports of adverse events 
relating to the use of cosmetics (vigilance cases) 
and serious risk alerts received from other countries 
(RAPEX). During 2019, 287 reactive surveillance 
cases were initiated.
Stakeholders and Partners
• In June, we were invited to present at the Irish 
Cosmetics, Detergent and Allied Products 
Association (ICDA) workshop: ‘Potential Regulatory 
Impact of Brexit for Cosmetic and Detergent 
Companies’. The workshop was attended by Irish 
and UK cosmetics and detergent responsible 
persons, manufacturers and distributors.
• In June, we launched an information campaign 
to raise awareness amongst consumers regarding 
appropriate use of sunscreen products. The 
information was published as video content on our 
website and social media platforms. Consumers 
were informed of topics such as understanding 
sunscreen labels, the difference between UVA 
and UVB radiation and, how to apply and store 
sunscreens.
• In September, we hosted Cosmetic Product 
Regulatory Information evenings, in Galway and 
Dublin. Responsible persons, manufacturers and 
distributors of cosmetic products attended as well 
as representatives of potential start-up businesses. 
We provided information on their responsibilities 
under the Cosmetics Regulation, and on topical 
issues, including Brexit. A number of one-to-one 
meetings were also held with stakeholders to 
provide more specific information. Information 
packs and other HPRA publications relating to 
cosmetic products were also provided. 
• In October, we hosted an information stand at the 
Taking Care of Business event in Athlone, which was 
attended by various stakeholders from SMEs and 
start-up businesses. We provided information on 
cosmetics regulation in general, as well as details 
of how the HPRA supports innovation and product 
development via our Innovation Office. Various 
HPRA publications relating to cosmetic products, 
innovation and medical devices were distributed.
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Cosmetic Products
The role of the HPRA is to regulate the 
manufacture, sale and supply of cosmetic 
products in Ireland. We identify and address 
cosmetic product quality and safety issues, in 
conjunction with the HSE, so that a cosmetic 
product will not compromise the health and 
safety of the consumer or the person  
applying the product. 
Inspections, Audits and Market 
Compliance
• The Joint Audit Programme (JAP) is a key 
element of the quality system adopted by good 
manufacturing practice (GMP) inspectorates in 
Europe and aims to ensure consistency of GMP 
inspection standards and a harmonised approach 
throughout Europe. In 2019, the HPRA participated 
in the JAP evaluation of the GMP compliance 
programme of another member state.
• Other EU contributions included participation in / 
leading on:  
– the drafting group for the new EU GMP Guide 
Annex 21 on importation;
– the development of a new risk assessment tool 
for the selection of medicinal products and active 
substances for surveillance testing; 
– a new risk-based tool to support inspection and 
surveillance relating to heparin manufacturers and 
their related products; 
– the development of a communication tool-kit for 
the Official Medicines Control Laboratory (OMCL) 
Network; and
– the drafting group on development of an 
interpretation guideline on the JAP audit 
checklist. 
 Innovation Support
• The HPRA continues to focus on supporting 
innovation as one of our five strategic goals. This 
reflects our role not just to protect but also to 
enhance public and animal health. Our supports for 
innovation aim to facilitate safe and timely access 
to innovative health products and to increase and 
improve treatment options for patients. They also 
benefit the HPRA by helping to inform our future 
development and allowing us to identify novel 
product types and technologies that require new 
or adapted regulatory science approaches. Our 
actions to support innovation in 2019 included the 
following:
– The HPRA’s Innovation Office continues to 
offer regulatory support and advice to anyone 
developing an innovative health product 
or technology. Over 65% of the queries to 
Innovation Office originate from academia or 
small and medium enterprises who may have 
limited access to specialist regulatory advice. 
Medical devices was the most frequent area 
addressed through Innovation Office queries 
followed closely by medicines;
– In 2019 the HPRA continued to take a lead role in 
the development of horizon scanning processes 
at a European level (within the EU Innovation 
Network) and at international level (within the 





Authorities (ICMRA). Horizon scanning is intended 
to identify novel health products at an early stage 
and inform the development of appropriate 
regulatory tools and approaches. This facilitates 
both effective regulation of such products and 
patient access; 
– Throughout 2019, our classification process 
continued to offer advice to stakeholders on 
the borderline between different regulatory 
frameworks including medicines, medical devices, 
cosmetics and other products; 
– The HPRA was part of a consortium of European 
medicines regulatory agencies who successfully 
applied to the European Commission for a 
Horizon 2020 funded coordination and support 
action. This project entitled ‘Strengthening 
regulatory sciences and supporting regulatory 
scientific advice’ (STARS) began in January 
2019. The first year of this project has focussed 
on establishing the current level of regulatory 
knowledge among academic researchers via 
questionnaires that have been completed by 
research centres, funding agencies and regulatory 
authorities. The project aims are set out below.
OTHER REGULATORY PROGRAMMES – HPRA Annual Report 2019
41
STARS: Project Aims
to improve the direct regulatory
impact of results obtained in
academic medical research
to reach academic researchers
very early in the planning of
relevant grant applications
to strengthen long-term
regulatory knowledge in general by 
reaching clinical scientists during 
professional training and qualification
• In our outreach activities to support innovation 
developments in Ireland:  
– The HPRA continued to meet and interact with a 
number of other state agencies and organisations 
who seek to support innovation in Ireland 
including the IDA, Enterprise Ireland, Health 
Innovation Hub Ireland and a number of third 
level institutions. We also met with individuals 
and organisations who are seeking to develop 
innovative health products and technologies to 
provide guidance on the regulatory requirements 
that will apply to their products. 
– The HPRA participated in a number of events 
around Ireland to promote our supports for 
innovation including the Taking Care of Business 
event organised by the Department of Business, 
Enterprise and Innovation in Athlone. In addition, 
reflecting our prominent role within the European 
network, the HPRA was invited to present on 
supports for innovation available from national 
competent authorities at the European Institute of 
Innovation and Technology (EIT) Health summit in 
Paris.   
– The HPRA continues to contribute to education 
programmes at both undergraduate and 
postgraduate levels. We also provided training 
placements to two 4th year pharmacy students 
as part of the five-year integrated pharmacist 
training programme.
• Stakeholder communications and engagement:
– We continued our public information campaign: 
Zero Gains. The campaign is focused on building 
awareness of the many and often serious side 
effects associated with the non-medical use 
of anabolic steroids. The 2019 media plan, 
incorporating three bursts in January, June and 
September, was a mix of social and digital media 
in addition to outdoor and in-gym adverts. The 
website - www.zerogains.ie - continued to be 
an important element of the campaign providing 
reliable and trustworthy information on the real 
risks of anabolic steroid use. The 2019 campaign 
also incorporated new outdoor advertising sites 
(including in Dundrum shopping centre), the 
addition of Snapchat to our social advertising 
presence, and a sponsored article and digital 
insert on the thejournal.ie website. The campaign 
continued to perform in line with expectations 
with engagement levels typically at or in excess of 
industry norms. 
– Throughout the year, we continued our media 
communications programme to proactively 
communicate important safety messages and 
to build awareness of the role of the HPRA. 
We issued approximately 20 press releases 
and website statements concerning safety 
and regulatory matters to ensure consumers, 




The HPRA is committed to a strategic focus 
on outreach and engagement with key 
partners and stakeholders so as to enhance 
and maximise the effectiveness of the 
regulatory system. 
received timely and accurate information 
and advice. In a number of instances, these 
communications resulted in national and regional 
media interviews with a HPRA spokesperson. In 
addition, we responded to more than 370 initial 
and follow-up queries from national, local and 
specialist media during the year. 
– The HPRA was pleased to participate again as 
one of a number of education partners working 
with the Irish Platform for Patient Organisations, 
Science & Industry (IPPOSI) to deliver the 2019 
Patient Education Programme in the area of 
health innovation. The programme, which is 
specifically tailored for Irish patient communities, 
is based on a ‘blended learning’ approach 
consisting of e-learning and face-to-face sessions. 
The HPRA module was focused on regulatory 
affairs, medicines safety, pharmacovigilance and 
medical devices. Graduates of the programme, 
including both patients and patient advocates, 
are empowered to work effectively with Irish and 
EU-level health research and technology partners, 
agencies and authorities. 
– The HPRA commenced work in 2019 on the 
establishment of our first ever patient forum. The 
objective of the forum, which will be established 
initially on a pilot basis and launch during 2020, is 
to improve two-way communication with patients 
so as to capture their views of the role and work 
of our organisation and the regulatory system. 
Identifying and acting upon patient perspectives 
has the potential to add real value to regulatory 
policies and decision-making. During 2019, we:
 Engaged with other health agencies and 
regulators, both nationally and at a European 
level, to identify best practices in this area;
 Developed a proposed forum structure / 
approach for the HPRA in addition to a draft 
role description for members;
 Issued a call for expressions of interest from 
potential members including graduates of 
the IPPOSI patient training programme and 
representatives from the patient associations 
representing the main disease areas in Ireland; 
 Identified initial topics for discussion by the 
forum including patients’ perspectives on the 
HPRA’s nest five year Strategic Plan 2021-2025 
and other topical issues such as Brexit and 
medicines shortages. Further topics will depend 
on areas of importance raised by members of 
the forum but will likely include the content, 
format and channels of communications 
between the HPRA and patients, and initiatives 
to help increase adverse reaction reporting 
rates.
 The response to the forum to date has been 
very positive among both organisations and 
perspective members and we look forward to its 
official launch in 2020.
– The HPRA website – www.hpra.ie – is a key 
communications channel and we continuously 
monitor and analyse key visitor and usage 
statistics. The key findings from 2019 included: 
 More than 780,000 users of our website 
during the past twelve months representing a 
significant 44% increase compared to 2018. 
 There were in excess of 4.4 million page views 
in total throughout the year, which is the highest 
annual number, recorded for our website. 
 Of those who accessed the site, more than 47% 
were mobile phone users. 
– The @TheHPRA Twitter account supports our 
communications activities and helps to direct 
additional traffic to the HPRA website. We 
continued to develop our Twitter activity during 
2019 and by year end we had grown our number 
of followers by more than 41% to 2,550. Among 
the highlights was our continued participation 
in an international social media campaign to 
promote the reporting of suspected side effects 
from medicines. This campaign was supported 
by a range of patient organisations and other 
national health agencies.  
– Our LinkedIn account continues to support the 
growth of our employer brand (see also page 
47). In addition, it facilities the dissemination of 
important regulatory and safety information to 
health and industry professionals. By end 2019, 
our total number of followers had grown to 8,332.
– Also during 2019, we continued to utilise our 
corporate Instagram account to highlight and 
promote certain activities and events. The use 
of Instagram stories was again a key component 
of our Zero Gains anabolic steroids information 
campaign.
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• European and international contribution: 
– Details of the extensive Brexit preparatory work 
carried out by the HPRA during 2019 are outlined 
on pages 12 to 15. 
– The HPRA continued to attend the quarterly EMA 
Management Board meetings:  
- At its October 2019 meeting, the Management 
Board elected HPRA Chief Executive, Dr 
Lorraine Nolan, as vice-chair of the Board 
for a three-year period. She has served as a 
member of EMA’s Management Board, which 
is an integral governance body of the Agency, 
since March 2016. The Board has a supervisory 
role with general responsibility for budgetary 
and planning matters, the appointment of the 
Executive Director and the monitoring of the 
Agency’s performance.
- During 2019, the Management Board meetings 
were held in Amsterdam following the EMA’s 
move from London in March. Initially, the 
Agency operated from temporary premises 
in Amsterdam Sloterdijk. Its newly built tailor-
made premises, located in the Zuidas area of 
Amsterdam, was officially handed over to the 
EMA in November 2019. The subsequent move 
into the new EMA building in January 2020 
marked the last step of the Agency’s relocation 
to the Netherlands.
- The coordination of Brexit related issues and 
oversight of activities linked to the relocation 
to new offices in Amsterdam were two items 
dominating the Management Board agenda 
throughout 2019. Other ongoing issues 
included the new veterinary legislation and 
clinical trials regulation implementation.
– We continued our role as a member of the 
European Heads of Medicine Agencies (HMA) 
Management Group, which contributes to the 
direction and oversight of the HMA, following 
appointment in 2018. In addition to attending 
the quarterly HMA meetings, which took place 
in Timisoara and Bucharest in Romania and in 
Helsinki and Levi in Finland, we also participated 
as part of the secretariat for the monthly meetings 
of the HMA Brexit Task Force. 
– Additionally, as part of our ongoing contribution 
to the European regulatory system, HPRA 
scientific and technical staff participated in a 
broad range of committees and working parties 
at the European Commission, EMA, HMA, CAMD 
and other fora (see Appendix 4).
– The HPRA continued to co-ordinate the 
International Coalition of Medicines Regulatory 
Authorities (ICMRA) innovation project as well as 
co-leading on a work stream with the EMA. We 
are also leading on the governance project, on a 
review of membership and on an update to the 
Terms of Reference. In addition, we assisted with 
the organisation of the ICMRA plenary meeting 
in San Diego by introducing and operating a 
registration and fee payment system.
– The project to provide technical assistance to 
the Zambia Medicines Regulatory Authority was 
completed. Close out of the project was finalised 
and a confirmation letter of completion received 
from the PM Group.
• HPRA information events and training seminars 
provide regulatory guidance and updates to a 
range of stakeholders. The HPRA also partners with 
other regulatory organisations to co-host relevant 
events. During 2019, we hosted the following 
meetings:  
– Brexit Stakeholder Information Day – 1 February
– Pangea XI and combating illicit online medicines 
– 12 to 14 March – Co-hosted with Interpol
– Permanent Forum on International Pharmaceutical 
Crime – 27 to 31 May 
– Joint Action on Market Surveillance (medical 
devices) – 10 to 12 September 
– Cosmetic Products Information Evenings – 10 and 
16 September in Galway and Dublin
– Medical Devices Distributor Day – 13 November 
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• Also in 2019, the TOPRA Annual Symposium was 
held in Dublin from 30 September to 2 October 
in co-operation with the HPRA. The Symposium, 
which is recognised as a key event in the European 
regulatory affairs calendar, gives participants access 
to the latest information and insights directly from 
regulators, key opinion leaders and innovators. Of 
note:  
– The theme for the 2019 event was: “Europe at the 
forefront of global healthcare regulation: Driving 
innovation through convergent approaches in 
medicines, devices and veterinary regulatory 
affairs”.
– More than 640 participants attended from 31 
countries representing over 300 entities, including 
22 regulatory authorities.
– Speakers included representatives from the World 
Health Organisation, the European Commission, 
the European Medicines Agency and various 
European national authorities. Attendees also 
heard from representatives of industry in addition 
to healthcare professional and patient groups. 
– HPRA staff members, as well as contributing to 
the planning for the event as part of the separate 
human medicines, veterinary medicines and 
medical devices symposium working parties, also 
delivered a broad range of presentations over the 
course of the three-day programme.
Key outreach and engagement figures 2019 2019
Public consultations held:
 - Proposed regulatory fees for human products 
 - Proposed regulatory fees for veterinary medicines
 - Public consultation on HPRA Strategic Plan 2021-2025
3
Public consultations responded to:
 - Included Department of Health; Department of Business, Enterprise and Innovation; EMA; and PSI 
13
Events managed by HPRA events teams 7
Freedom of information requests 33
Requests received in accordance with the Data Protection Acts 3
Parliamentary questions 52
Queries from Government departments or members of the Oireachtas 101
Protected disclosures received by external persons under section 7(2) of the protected Disclosures Act, of 





Protected disclosures from HPRA staff members 0
Complaints 1
Customer service queries 3,336
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Human Resources and Change
Our HR and Change (HR&C) Strategy 2016 – 
2020 continued to provide the framework for the 
development of our internal capabilities in the HPRA. 
The six core themes identified within the strategy 
drive our progress with various initiatives delivered 
throughout the year. 
Highlights during 2019 include:
• Retention and Engagement: 
– Employee engagement pulse surveys continued 
with feedback and actions communicated at 
departmental level. Related support activities 
were undertaken. 
– The HPRA recognition programme was finalised 
and went live from Q4 with the first ‘Accolade’ 
award winners and the commencement of the 
celebration of service. 
– 2019 saw the rollout of our diversity and inclusion 
policy and related initiatives including a focus 
on Pride in June. We achieved the Investors in 
Diversity Award and a number of employees 
completed LGBT ally training. 
– The health and wellbeing agenda continued as a 
key focus with a number of activities held and the 
HPRA officially becoming a See Change partner. 
In addition, we received Marchathon Best Large 
Organisation and Top Coordinator awards, the 
Gold Active @ Work award from the Irish Heart 
foundation and successfully completed our 
interim review for the Keep Well Mark.
– A review and edit of the LearningConnect 
web resource was completed to support a 
redesigned induction programme and to address 





The HPRA is committed to having the necessary 
corporate functions, systems and supports in 
place to deliver on our public health mission. 
We must ensure that our organisational 
capabilities continue to expand and evolve in 
line with regulatory and scientific developments 
and that we adapt to other changes in our 
operating environment.
• Career Development: 
– The cross-organisational working group continued 
the development of skill matrices for a number 
of roles and drafted changes to a new capability 
framework.
– The second iteration of the graduate programme 
commenced in September 2019. Recruitment 
for the third iteration was also completed with 
graduate resources confirmed to commence in 
September 2020. A graduate blog series was also 
published via LinkedIn to support the promotion 
of the programme.
• HR and Change: 
– The new HR Business Partner model was finalised 
and launched in Q4.
– Our social media presence was a key focus for 
our employer brand, achieved through targeted 
monthly planning of content, increased focus 
through recruitment campaigns and monitoring of 
analytics.
– The HR&C department commenced ICAgile 
Accreditation in Q4 to implement an Agile HR 
methodology to support the organisation more 
effectively with increasing levels of complexity 
and change within our operating environment. 
Further training will be completed in Q1 2020 
with a view to full accreditation being achieved in 
2020. 
• Organisation Design: 
– The restructure of the new Medical Devices 
department was completed with all related 
resourcing activities undertaken. The team 
competency matrix was finalised and training 
needs assessed. The project concluded 
successfully with development of the 
management team supported formally to assist 
during the transition period.
– Support was provided in respect of the re-
development and re-alignment of roles and 
responsibilities within the GMP Inspections team 
– Workshops, to examine re-alignment of some 
activities across the departments with human 
medicines responsibilities and to reduce handoff 
time and optimise processes, were facilitated and 
supported.
• Talent Management: 
– Preparatory activities were completed ahead of 
the successful go live of online recruitment via 
the HPRA Recruitment Portal in Q3 with a series 
of training videos and supporting instructional 
documentation drafted to facilitate the transition. 
– Recruitment activities saw an increase of 39% 
from 2018 to 2019 in terms of competitions 
completed which included additional headcount 
to support the additional Brexit related work.
– Phase two of the MDP (management 
development programme) was completed while 
phase three commenced. Phase one of the LDP 
(leadership development programme) was also 
completed in addition to a needs analysis for the 
design of phase two. 
– The redesign of the new manager training 
programme was finalised and the first programme 
of our iLM accredited train the trainer (TTT) was 
completed.
• Change Management: 
– Support was provided for procurement and 
selection of an interim Senior ICT Manager, which 
included operational support for the team.
– Supported work on researching and developing a 
remote working pilot.
– Continued to provide representation and change 
management support in respect of the Eolas 
workflow system.  
– Provided of ongoing change management 
support to the project group implementing the 
new EU medical device Regulations.


















• Enhancements continued to Eolas, the HPRA’s 
workflow and data management system, which is a 
central platform to support its regulatory activities. 
The functionality of Eolas will continue to be 
enhanced and its footprint expanded to integrate 
other HPRA processes and procedures.
• A number of significant upgrades to additional 
systems were completed during the year giving 
added capability to users in support of their 
activities.
• Upgrades were made to the office and collaboration 
infrastructure including the introduction of Skype 
for Business and enhancements to the technology 
available in meeting rooms.
• There were 560,178 regulatory submissions made 
through the Common Electronic Submission Portal 
(CESP), which is managed by the HPRA on behalf 
of the wider EU regulatory community. By year-end, 
there were 6,578 organisations availing of CESP 
with over 23,766 individual users.
Quality Management
• The HPRA’s quality management team was 
responsible for the continued implementation of 
policies and procedures relating to the General 
Data Protection Regulation (GDPR). There were 
three data subject requests received in 2019. 
All requests were managed within the required 
timelines.
• New guidance for stakeholders relating to the 
import/export licensing of cannabis products for 
medical use was published on the HPRA website. 
Finance
• The HPRA is committed to the highest standards of 
corporate governance. During 2019, the financial 
statements for the previous year were prepared and 
submitted for audit to the Comptroller and Auditor 
General and subsequently published in the HPRA’s 
2018 Annual Report. All financial transactions 
during the period were reflected and reported upon 
in these statements. 
• The annual review of regulatory fees for 2020, 
incorporating a public consultation, was completed 
followed by the publication of required fee 
changes. 
• An internal audit review took place and a report was 
issued on income management. 
Energy Usage
• The HPRA, as a public sector body, is required to 
report annually on its energy usage and actions 
taken to reduce consumption in accordance with 
the European Union (Energy Efficiency) Regulations 
2014 (S.I. No. 426 of 2014). As an organisation, 
we use electricity for lighting, air conditioning or 
heating as required and the provision of hot water; 
natural gas is used for central heating. In 2019, the 
HPRA consumed 718.2 MWh* of energy consisting 
of:  
– 499.7 MWh of electricity
– 218.5 MWh of fossil fuels
– 0 MWh of renewable fuels.
 Total energy reduction at year end was 38.6%, 
exceeding the goal of 33% by 2020 (as calculated 
and published by the Sustainable Energy Authority 
of Ireland (SEAI). 
 * published by the SEAI 
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• The Authority of the HPRA met six times in 2019 
and considered a number of strategic matters 
including preparations for Brexit, corporate policy, 
planning, and financial matters. The latter included 
monthly management accounts, annual budgets 
and the financial statements for 2018. The Authority 
also reviewed update reports from the Statutory 
Advisory Committees and the Audit and Risk 
Committee. In addition, it reviewed the licences for 
all medicinal healthcare products as approved by 
the Management Committee.
 The number of meetings attended by each 












the period the 
member was on 
the Authority
Ms. Ann Horan 
(Chairperson)
6 6
Mr. Pat Brangan 6 6

















– The Audit and Risk Committee, a subcommittee 
to the Authority, met four times in 2019. Further 
details are provided in the HPRA’s Financial 
Statements. 
– The Advisory Committee for Human Medicines 
met on two occasions in 2019. The Clinical 
Trials Sub-Committee is a sub-committee to the 
Advisory Committee for Human Medicines and it 
met twelve times in the past year.
– The Advisory Committee for Veterinary Medicines 
met twice as did the Advisory Committee for 
Medical Devices.
– The National Committee for the Protection of 
Animals Used for Scientific Purposes, a statutory 
committee to provide guidance to the regulator 
and those working in this area, met twice in 2019.
• Decisions of the Authority: 
 The terms of reference of the Authority, which 
are published on the HPRA website, include 
an overview of how the Authority operates, an 
overview of all decisions taken by the Authority and 
those devolved to the Management Committee. 
 The following decisions are reserved functions of 
the Authority: 
– The Authority takes decisions relating to very 
significant and serious public and/or animal 
health matters except in circumstances where a 
meeting of the Authority cannot be convened, 
in which case the Management Committee takes 
the decision and informs the Chairperson at the 
earliest opportunity and the Authority as soon as 




– The Authority refuses applications, or suspends, 
revokes or terminates authorisations as set out in 
legislation except in circumstances where: 
(a) the urgency is such that a meeting of the 
Authority cannot be convened, or 
(b) the application or authorisation is subject to a 
binding European decision, or 
(c) the application or authorisation is for a clinical 
trial or clinical investigation; in which case the 
Management Committee takes the decision 
and informs the Authority. 
– Through its Audit Committee, the Authority 
approves the internal financial controls and the 
financial audit function and satisfies itself that the 
financial controls and systems of risk management 
are robust and defensible. The Authority appoints 
the internal financial auditor. 
- The Authority approves the investment policy, 
major investments, capital projects and the terms 
of major contracts. 
- Significant acquisitions and the disposal or 
retirement of assets above a threshold set by the 
Authority are subject to Authority approval. 
- The Authority approves treasury policy and risk 
management policies. 
- The Authority approves corporate plans as 
required. 
- The Authority approves the annual budget, 
monitors expenditure and supervises the 
preparation and submission of the annual 
statutory accounts. 
- The Authority makes an annual report on the 
activities of the HPRA, including a financial 
statement, to the Minister for Health. This report 
is then published. 
- The Authority selects and appoints the Chief 
Executive, with the consent of the Minister for 
Health. The terms of office and the remuneration 
of the Chief Executive are determined by the 
Minister for Health, after consultation with the 
Authority and with the consent of the Minister for 
Finance. The Authority, through its Performance 
Review Committee, conducts a process of annual 
performance appraisal of the Chief Executive. 
Succession planning for the role of Chief 
Executive is also undertaken by the Authority. 
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Governance Statement and 
Authority Member’s Report
Governance
The Health Products Regulatory Authority (the 
HPRA) was established under the terms of the Irish 
Medicines Board Act, 1995 (as amended), and is 
governed by an Authority which was appointed 
by the Minister for Health. The Authority of the 
HPRA (the Authority) consists of a chairperson 
and eight non-executive members. The Authority 
is accountable to the Minister for Health and is 
responsible for ensuring good governance, and 
performs this task by setting strategic objectives 
and targets and taking strategic decisions on 
all key business issues. The regular day-to-day 
management, control and direction of the HPRA 
are the responsibility of the Chief Executive and 
the Management Committee. The Chief Executive 
and the Management Committee must follow the 
broad strategic direction set by the Authority, and 
must ensure that all Authority members have a clear 
understanding of the key activities and decisions 
related to the HPRA, and of any significant risks 
likely to arise. The Chief Executive acts as a direct 
liaison between the Authority and management of 
the HPRA.
On 1 July 2014 the organisation changed its name 
from the Irish Medicines Board, as provided for 
in Section 36 of the Health (Pricing and Supply of 
Medical Goods) Act 2013 and SI (205/2014) Health 
(Pricing and Supply of Medical Goods) Act 2013 
(Commencement) order 2014.   
Authority Responsibilities
The work and responsibilities of the Authority are 
set out in the Irish Medicines Board Act, 1995 (as 
amended), as well as in the ‘Terms of Reference 
and Rules of Procedure’ of the HPRA, which also 
contains the matters specifically reserved for 
Authority decision. Standing items considered by 
the Authority include:
• declaration of interests,
• reports from committees,
• financial reports / management accounts,
• performance reports, and
• reserved matters.
The Authority is required by the Irish Medicines 
Board Act, 1995 to prepare financial statements for 
each financial year which give a true and fair view of 
the financial position of the HPRA and of its surplus 
or deficit for that period.
In preparing those statements the Authority is 
required to:
• select suitable accounting policies and apply them 
consistently,
• make judgements and estimates that are 
reasonable and prudent,
• prepare the financial statements on a going 
concern basis unless it is inappropriate to presume 
that the HPRA will continue in existence, and
• state whether applicable accounting standards 
have been followed, subject to any material 
departures disclosed and explained in the financial 
statements.
 
The Authority is responsible for keeping adequate 
accounting records which disclose, with reasonable 
accuracy at any time, the financial position of 
the HPRA and which enable it to ensure that 
the financial statements comply with the Irish 
Medicines Board Act, with accounting standards 
generally accepted in Ireland and with accounting 
directions issued by the Minister for Health.  The 
maintenance and integrity of the corporate and 
financial information on the HPRA’s website is the 
responsibility of the Authority.
The Authority is responsible for approving the 
annual plan and budget. It is also responsible for 
safeguarding the assets of the HPRA and hence 
for taking reasonable steps for the prevention and 
detection of fraud and other irregularities.
The Authority considers that, except for the non-
compliance with the requirements of FRS102 
in relation to retirement benefits, the financial 
statements of the HPRA give a true and fair view of 
the financial performance and the financial position 
of the HPRA at 31 December 2019.
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Audit and Risk Committee
The HPRA has an audit and risk committee 
comprising three Authority members, which met 
on 4 occasions during 2019. This committee is 
responsible for reviewing internal control matters, 
together with any other issues raised by the external 
auditors, the Authority or management. The external 
auditor is invited annually to meet with the audit 
and risk committee to brief them on the outcome of 
the external audit, and the audit and risk committee 
also meets annually with the internal auditor. During 
2019 the internal auditor carried out an internal 
audit review on the area of income management. 
The audit and risk committee has also been involved 
with the review of the quality systems as described 
below.
Quality Systems
During 2019, the finance section of the HPRA 
continued the process of implementing and 
reviewing standard operating procedures (SOPs) 
under the quality management system. This process 
involved a critical review and analysis of internal 
controls and processes throughout the section 
with particular emphasis on risk management. 
This system now underpins the internal control 
environment and feeds into the internal audit 
process and ultimately into the audit and risk 
committee.
Remuneration Policy – Authority 
Members and Executive Directors
Remuneration and travel expenses paid to Authority 
members are disclosed in note 17 to the Financial 
Statements. The Chairperson receives remuneration 
as directed by the Minister for Health in accordance 
with the Irish Medicines Board Act, 1995. Other 
Authority members receive remuneration under the 
terms of the Health (Miscellaneous Provisions) Act 
2017. All Authority members are entitled to receive 
travel expenses in accordance with circulars issued 
by the Department of Health. The Chief Executive is 
remunerated in accordance with guidelines issued 
from Government and other Executive Directors are 
paid in accordance with Department of Health pay 
scales. The remuneration of the Chief Executive and 
Executive Directors are disclosed in note 18 to the 
Financial Statements.
Internal Control
The Authority is responsible for the HPRA’s systems 
of internal control. Such systems can only provide 
reasonable and not absolute assurance against 
material misstatement or loss. The systems of 
internal controls in use in the HPRA are described 
more fully in the Chairperson’s report on pages 54 
to 55.
Disclosures Required by Code of Practice 
for the Governance of State Bodies 
(2016)
The Authority is responsible for ensuring that the 
HPRA has complied with the requirements of the 
Code of Practice for the Governance of State 
Bodies, as published by the Department of Public 
Expenditure and Reform in August 2016. The 
following disclosures are required by the Code, 
and are contained in the notes to the financial 
statements:
• employee short term benefits breakdown,
• consultancy costs,
• legal costs and settlements,
• travel and subsistence expenditure, and
• hospitality expenditure.
Statement of Compliance
The Authority has adopted the Code of Practice for 
the Governance of State Bodies (2016) and has put 
procedures in place to ensure compliance with the 
Code. The HPRA was in full compliance with the 
Code of Practice for the Governance of State Bodies 
for 2019.
Performance Review
The Authority carried out a self-assessment 
evaluation of its own performance and its 
committees during the year ended 31 December 
2019.
On behalf of the Authority
 
 
Date: 18 June 2020
Ms. Ann Horan 
Chairperson 
Mr. David Holohan 
Authority Member
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Statement on Internal Control
Scope of Responsibility
I, as Chairperson, acknowledge the Authority’s 
responsibility for ensuring that an effective system 
of internal control is maintained and operated. This 
responsibility takes account of the requirements of 
the Code of Practice for the Governance of State 
Bodies (2016).
Purpose of the System of Internal 
Control
The system of internal control is designed to 
manage risk to a tolerable level rather than to 
eliminate it. The system can therefore only provide 
reasonable and not absolute assurance that 
assets are safeguarded, transactions authorised 
and properly recorded and that material errors or 
irregularities are either prevented or detected in a 
timely way.
The system of internal control, which accords with 
guidance issued by the Department of Public 
Expenditure and Reform, has been in place in the 
HPRA for the year ended 31 December 2019 and up 
to the date of approval of the financial statements.
Capacity to Handle Risk
The HPRA has an audit and risk committee 
comprising three Authority members, which met on 
4 occasions during 2019.
The HPRA has outsourced the internal audit function 
to an independent professional firm, who conduct a 
programme of work as agreed with the audit and risk 
committee. During 2019 one internal audit review 
was conducted. 
The HPRA have developed a risk management 
framework, which sets out its risk appetite, the risk 
management processes in place and details the 
roles and responsibilities of staff in relation to risk. 
This framework has been made available to all 
staff, who are expected to work within the HPRA’s 
risk management policies, to alert management on 
emerging risks and control weaknesses, and assume 
responsibility for risks and controls within their own 
area of work. 
Risk and Control Framework
The HPRA has implemented a risk management 
system which identifies and reports key risks and the 
management actions being taken to address, and to 
the extent possible, to mitigate those risks.
A risk register is in place which identifies the 
key risks facing the HPRA, and these have been 
identified, evaluated and graded according to their 
significance. The register is reviewed and updated 
by management, considered by the audit and risk 
committee twice per year and presented to the 
Authority. The outcome of these assessments is used 
to plan and allocate resources to ensure risks are 
managed to an acceptable level.
The risk register details the controls and actions 
needed to mitigate risks and responsibility for 
operation of controls assigned to specific staff. I 
confirm that a control environment containing the 
following elements is in place:
• procedures for all key business processes have 
been documented,
• financial responsibilities have been assigned 
at management level with corresponding 
accountability,
• there is an appropriate budgeting system with 
an annual budget, which is kept under review by 
senior management,
• there are systems aimed at ensuring the security 
of the information and communication technology 
systems, and
• there are systems in place to safeguard the assets.
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Ongoing Monitoring and Review
Formal procedures have been established for 
monitoring control processes, and any control 
deficiencies are communicated to those responsible 
for taking corrective action, and to management and 
the Authority, where relevant, in a timely manner. 
I confirm that the following ongoing monitoring 
systems are in place:
• key risks and related controls have been identified, 
and processes have been put in place to monitor 
the operation of those key controls and report any 
identified deficiencies,
• reporting arrangements have been established 
at all levels where responsibility for financial 
management has been assigned, and
• there are regular reviews by senior management 
of periodic and annual performance and financial 
reports, which indicate performance against 
budgets.
Procurement
I confirm that the HPRA has procedures in place to 
ensure compliance with current procurement rules 
and guidelines, and that during 2019 the HPRA 
complied with those procedures, with the following 
exception.
In 2019 the HPRA incurred €117K of 
telecommunications expenditure on foot of 
documented business justifications and memos from 
senior management. The expenditure was incurred 
on four contracts which were rolled over due to 
overriding business priorities, while also waiting on 
the results of the unified communications project, 
together with the findings of the HPRA digital 
transformation strategy. This project is expected to 
be completed during 2020, when this expenditure 
will be subject to a procurement tender process.
Review of Effectiveness
I confirm that the HPRA has procedures to monitor 
the effectiveness of its risk management and control 
procedures. The HPRA’s monitoring and review of 
the effectiveness of the system of internal control is 
informed by the work of the internal and external 
auditors, the audit and risk committee which 
oversees their work, and the senior management 
within the HPRA, responsible for the development 
and maintenance of the internal control framework.
I confirm that the Authority conducted an annual 
review of the effectiveness of the internal controls 
for 2019. This review was carried out at its meeting 
on 3 March 2020.
Internal Control Issues
No weaknesses in internal control other than the one 
outlined above were identified in relation to 2019 
that require disclosure in the financial statements.
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Ms. Ann Horan 
Chairperson to the Authority 
Date: 18 June 2020
Comptroller and Auditor General  
 
Report for presentation to the 
Houses of the Oireachtas
Qualified opinion on financial statements
I have audited the financial statements of the Health 
Products Regulatory Authority (the Authority) for the 
year ended 31 December 2019 as required under 
the provisions of section 18 of the Irish Medicines 
Board Act, 1995. The financial statements have been 
prepared in accordance with Financial Reporting 
Standard (FRS) 102 – The Financial Reporting 
Standard applicable in the UK and the Republic of 
Ireland and comprise
• The statement of income and expenditure and 
retained revenue reserves
• The statement of financial position
• The statement of cash flows and
• The related notes, including a summary of 
significant accounting policies.
In my opinion, except for the non-compliance with 
the requirements of FRS 102 in relation to retirement 
benefit entitlements referred to below, the financial 
statements give a true and fair view of the assets, 
liabilities and financial position of the Authority at  
31 December 2019 and of its income and 
expenditure for 2019 in accordance with FRS 102.
Basis for qualified opinion on financial 
statements
In compliance with the directions of the Minister 
for Health, the Authority accounts for the costs of 
retirement benefit entitlements only as they become 
payable. This does not comply with FRS 102 which 
requires that the financial statements recognise the 
full cost of retirement benefit entitlements earned in 
the period and the accrued liability at the reporting 
date. The effect of the non-compliance on the 
Authority’s financial statements for 2019 has not 
been quantified.
I conducted my audit of the financial statements 
in accordance with the International Standards on 
Auditing (ISAs) as promulgated by the International 
Organisation of Supreme Audit Institutions. My 
responsibilities under those standards are described 
in the appendix to this report. I am independent 
of the Authority and have fulfilled my other ethical 
responsibilities in accordance with the standards.
I believe that the audit evidence I have obtained is 
sufficient and appropriate to provide a basis for my 
opinion.
Report on information other than the 
financial statements, and on other 
matters 
The Authority has presented certain other 
information together with the financial statements. 
This comprises the annual report, the governance 
statement and Authority members’ report and the 
statement on internal control. My responsibilities to 
report in relation to such information, and on certain 
other matters upon which I report by exception, are 
described in the appendix to this report.
I have nothing to report in that regard.
Andrew Harkness 
For and on behalf of the Comptroller  
and Auditor General 
25 June 2020 
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Appendix to the report 
Responsibilities of Authority Members
As detailed in the governance statement and 
Authority members’ report, the Authority members 
are responsible for
• The preparation of financial statements in the form 
prescribed under section 18 of the Irish Medicines 
Board Act 1995
• Ensuring that the financial statements give a true 
and fair view in accordance with FRS 102
• Ensuring the regularity of transactions
• Assessing whether the use of the going concern 
basis of accounting is appropriate, and
• Such internal control as they determine 
is necessary to enable the preparation of 
financial statements that are free from material 
misstatement, whether due to fraud or error.
Responsibilities of the Comptroller and 
Auditor General
I am required under section 18 of the Irish Medicines 
Board Act 1995 to audit the financial statements of 
the Authority and to report thereon to the Houses of 
the Oireachtas.
My objective in carrying out the audit is to obtain 
reasonable assurance about whether the financial 
statements as a whole are free from material 
misstatement due to fraud or error. Reasonable 
assurance is a high level of assurance, but it is not 
a guarantee that an audit conducted in accordance 
with the ISAs will always detect a material 
misstatement when it exists. Misstatements can 
arise from fraud or error and are considered material 
if, individually or in the aggregate, they could 
reasonably be expected to influence the economic 
decisions of users taken on the basis of these 
financial statements.
As part of an audit in accordance with the ISAs, 
I exercise professional judgement and maintain 
professional scepticism throughout the audit. In 
doing so,
• I identify and assess the risks of material 
misstatement of the financial statements whether 
due to fraud or error; design and perform audit 
procedures responsive to those risks; and obtain 
audit evidence that is sufficient and appropriate 
to provide a basis for my opinion. The risk of not 
detecting a material misstatement resulting from 
fraud is higher than for one resulting from error, 
as fraud may involve collusion, forgery, intentional 
omissions, misrepresentations, or the override of 
internal control.
• I obtain an understanding of internal control 
relevant to the audit in order to design 
audit procedures that are appropriate in the 
circumstances, but not for the purpose of 
expressing an opinion on the effectiveness of the 
internal controls.
• I evaluate the appropriateness of accounting 
policies used and the reasonableness of 
accounting estimates and related disclosures.
• I conclude on the appropriateness of the use of 
the going concern basis of accounting and, based 
on the audit evidence obtained, on whether a 
material uncertainty exists related to events or 
conditions that may cast significant doubt on the 
Authority’s ability to continue as a going concern. 
If I conclude that a material uncertainty exists, I 
am required to draw attention in my report to the 
related disclosures in the financial statements or, 
if such disclosures are inadequate, to modify my 
opinion. My conclusions are based on the audit 
evidence obtained up to the date of my report. 
However, future events or conditions may cause 
the Authority to cease to continue as a going 
concern.
• I evaluate the overall presentation, structure and 
content of the financial statements, including the 
disclosures, and whether the financial statements 
represent the underlying transactions and events 
in a manner that achieves fair presentation.
I communicate with those charged with governance 
regarding, among other matters, the planned scope 
and timing of the audit and significant audit findings, 
including any significant deficiencies in internal 
control that I identify during my audit.
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Information other than the financial 
statements
My opinion on the financial statements does not 
cover the other information presented with those 
statements, and I do not express any form of 
assurance conclusion thereon.
In connection with my audit of the financial 
statements, I am required under the ISAs to read 
the other information presented and, in doing so, 
consider whether the other information is materially 
inconsistent with the financial statements or with 
knowledge obtained during the audit, or if it 
otherwise appears to be materially misstated. If, 
based on the work I have performed, I conclude 
that there is a material misstatement of this other 
information, I am required to report that fact.
Reporting on other matters
My audit is conducted by reference to the special 
considerations which attach to State bodies in 
relation to their management and operation. I report 
if I identify material matters relating to the manner in 
which public business has been conducted.
I seek to obtain evidence about the regularity of 
financial transactions in the course of audit. I report 
if I identify any material instance where public 
money has not been applied for the purposes 
intended or where transactions did not conform to 
the authorities governing them.
I also report by exception if, in my opinion,
• I have not received all the information and 
explanations I required for my audit, or
• The accounting records were not sufficient to 
permit the financial statements to be readily and 
properly audited, or
• The financial statements are not in agreement with 
the accounting records.
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 Note  2019  2018
  € €
Fee Income  3    27,932,876     23,901,603
Department of Health Funding 3   4,964,255   4,316,000 
Other Income  4             805,824     888,884 
   
        33,702,955    29,106,487  
Salaries and Wages  5    23,862,438     21,160,214 
Other Operating Costs  6          7,639,373     5,885,565 
Depreciation  2          1,274,848     1,593,390 
   
        32,776,659    28,639,169 
 
Surplus for the year before write
back of Superannuation contributions   926,296   467,318 
 
Staff Superannuation Contributions     691,855     696,116 
 
 
Surplus for the year   1,618,151  1,163,434 
 
Balance brought forward         29,488,113     28,324,679 
 




The Statement of Income and Expenditure and Retained Revenue Reserves includes all gains and losses recognised in the 
year. The Statement of Cash Flows and the notes on pages 62 to 72 form part of the financial statements.  








Statement of Income and Expenditure and Retained Revenue Reserves
For the year ended 31 December 2019
Ms. Ann Horan
Chairperson
Date: 18 June 2020
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 Note  2019  2018
  € €
Fixed Assets  
Property, Plant and Equipment  2       24,896,454      24,427,830  
 
Current Assets
Debtors and Prepayments 7    2,514,984     2,198,340  
Inventory of Stationery    5,533      3,498 
Cash and Cash Equivalents 9     2,290,820        10,162,555  
Short Term Deposits 10    17,658,240        8,216,814  
       22,469,577      20,581,207  
Current Liabilities - Amounts falling
due within one year
Creditors and Accruals  8    12,293,087          10,760,912  
Mortgage  13            793,332      793,332  
   
       13,086,419      11,554,244 
 
Net Current Assets         9,383,158            9,026,963 
 
Long Term Liabilities - Amounts falling 
due after more than one year
Mortgage  13    3,173,348            3,966,680  
 
 




Retained Revenue Reserves  12    31,106,264        29,488,113  
  





Statement of Financial Position





Date: 18 June 2020
The Statement of Cash Flows and the notes on pages 62 to 72 form part of the financial statements.
On behalf of the Authority
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 Note  2019  2018
  € €
Cash flows from Operating Activities
 
Surplus for financial year   1,618,151  1,163,434
Depreciation of property, plant and equipment  1,274,848  1,593,390
(Profit)/Loss on Disposal of property, plant and equipment  (49)  26
(Increase) in Debtors  (316,644) (793,653)
(Increase) / Decrease in Stock  (2,035) 1,635
Increase in Creditors - amounts  
falling due within one year  1,532,175 1,702,799
Deposit Interest   (16,737)  (16,064)
Bank Interest  174,075 181,171
Cash from Operations  4,263,784  3,832,738
Bank Interest Paid   (174,075) (181,171)
Net Cash generated from Operating Activities  4,089,709 3,651,567
Cash flows from Investing Activities  
Deposit Interest Received  16,737 16,064
(Increase) / Decrease in Bank Deposits   (9,441,426) 4,085,613
Payments to acquire property, plant and equipment   (1,744,103) (681,407)
Receipts fom sales of property, plant and equipment  680  0
 
Net cash from Investing Activities  (11,168,112) 3,420,270
Cash flows from Financing Activities
Repayment of Borrowings  (793,332)  (793,332)
Net cash used in Financing Activities  (793,332)  (793,332)
 
Net increase/(decrease) in Cash and Cash Equivalents  (7,871,735) 6,278,505
Cash and Cash Equivalents at beginning of year  10,162,555  3,884,050
 
Cash and Cash Equivalents at end of year 9  2,290,820 10,162,555
 
 
Statement of Cash Flows
For the year ended 31 December 2019
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Notes to the Financial Statements
For the year ended 31 December 2019
1. Accounting Policies    
      
A. General information    
The Health Products Regulatory Authority (HPRA) 
is a public statutory body established under the 
Irish Medicines Board Act 1995 (as amended). The 
principal place of business is at Earlsfort Centre, 
Earlsfort Terrace, Dublin 2. The Health Products 
Regulatory Authority is the competent Authority for 
the regulation of medicines, medical devices and 
other health products in Ireland.    
     
B. Compliance with FRS 102    
   
The financial statements of the HPRA for the year 
ended 31 December 2019 have been prepared in 
accordance with FRS 102 (the financial reporting 
framework applicable in the UK and Ireland, and 
promulgated by Chartered Accountants Ireland), as 
modified by the directions of the Minister for Health 
in relation to superannuation. In compliance with the 
directions of the Minister for Health, HPRA accounts 
for the costs of superannuation entitlements only as 
they become payable (see K). This basis of accounting 
does not comply with FRS102, which requires such 
costs to be recognised in the year in which the 
entitlement is earned. The HPRA is availing of the 
reduced disclosures allowed by FRS 102 in relation 
to legal provisions, in instances where full disclosure 
might prejudice seriously its position in relation to 
disputes with other parties on the subject matter 
of the provision. In all other respects, the financial 
statements comply with FRS 102.    
   
C. Basis of preparation     
  
The financial statements have been prepared 
under the historical cost convention. The following 
accounting policies have been applied consistently in 
dealing with items which are considered material in 
relation to the Health Products Regulatory Authority’s 
financial statements.     
       
    
D. Critical accounting estimates and judgements
      
The preparation of the financial statements requires 
management to make judgements, estimates and 
assumptions that affect the amounts reported for 
assets and liabilities as at the reporting date and 
the amounts reported for revenues and expenses 
during the year. However, the nature of estimation 
means that actual outcomes could differ from those 
estimates. The following may involve a higher degree 
of judgement and complexity: 
  
(a) Provisions     
Provisions for legal obligations which it knows to 
be outstanding at the period-end date. These  
provisions are generally made based on historical or 
other pertinent information, adjusted for recent trends 
where relevant. However, they are estimates of the 
financial costs of events that may not occur for some 
years. As a result of this and the level of uncertainty 
attaching to the final outcomes, the actual outturn 
may differ significantly from that estimated. 
(b) Bad and Doubtful Debts   
The HPRA makes an estimate of the recoverable 
value of trade and other receivables. The HPRA 
uses estimates based on historical experience in 
determining the level of bad debts, which the 
Authority believes will not be collected. These 
estimates include such factors as the current credit 
rating, the ageing profile, historical experience of the 
particular trade receivable and objective evidence of 
impairment of the asset. Any significant reduction in 
the level of bad debt provision would have a positive 
impact on the annual surplus/deficit. The level of 
provisioning required is reviewed on an on-going 
basis and has been disclosed in the notes to the 
financial statements.
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Notes to the Financial Statements
For the year ended 31 December 2019
E. Revenue recognition    
   
Revenue is measured at the fair value of the 
consideration received.    
- In the case of applications for marketing 
authorisations (new applications, variations to 
existing authorisations, or transfers) and clinical trial 
applications, income is recognised on a straight line 
basis over the specified timeline for the processing 
of the application by the Authority. 
- In the case of wholesale and manufacturing licences 
and maintenance of marketing authorisations, fees 
are payable annually and a full year’s income is 
accrued in each financial year.    
       
       
  
F. Expenditure recognition    
   
Expenditure is recognised in the financial statements 
on an accruals basis.     
       
    
G. Reporting currency and currency 
translation      
 
The financial statements are prepared in euros. 
Transactions in currencies other than euro are 
recorded at the rates ruling at the date of the 
transactions or at a contracted date.  Monetary assets 
and liabilities are translated into euro at the reporting 
date or at a contracted date. Exchange differences are 
dealt with in the statement of income and expenditure 
and retained revenue reserves.    
       
      
       
  
H. Property, plant and equipment   
    
Plant and equipment excluding Premises
Plant and equipment excluding premises are stated at 
cost less accumulated depreciation.   
Depreciation is calculated in order to write off the cost 
of property, plant and equipment to their estimated 
residual values over their estimated useful lives by 
equal annual instalments. 
The estimated useful lives of property, plant and 
equipment by reference to which depreciation has   
been calculated are as follows:    
     
Fixtures and Fittings:   5 years  
Computer Equipment :   3 years  
Improvements to Premises :  10 years  
       
   
Premises     
The HPRA purchased its premises at Kevin O’Malley 
House, Earlsfort Centre, Earlsfort Terrace, Dublin 2   
on 22 December 2004. The value capitalised was 
equal to the purchase price plus those costs directly  
attributable to bringing the asset into use. 
No depreciation has been calculated on the value of 
premises, as the remaining useful economic life is   
estimated to be greater than 50 years.   
      
       
I. Taxation      
 
The HPRA is exempt from liability to Corporation Tax 
under Section 227 of the Taxes Consolidation Act, 
1997.       
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Notes to the Financial Statements
For the year ended 31 December 2019
J. Debtors      
 
Known bad debts are written off and specific provision 
is made for any amount the collection of which is 
considered doubtful.      
     
       
K. Superannuation     
  
The superannuation scheme operated by the 
HPRA is in accordance with the Local Government 
(Superannuation Revision) (Consolidation) Scheme, 
1986. It is an unfunded statutory scheme and benefits 
are met from current income as they arise.
The scheme is a defined benefit scheme for 
employees. No provision has been made in respect 
of benefits payable. Pension payments under the 
scheme are charged to the statement of income and 
expenditure when paid. Contributions from employees 
who are members of the scheme are credited to the 
statement of income and expenditure when received. 
The surplus/(deficit) for the year is shown both before 
and after superannuation deductions.
HPRA also operate the Single Public Service Pension 
Scheme. All new entrants into the public sector with 
effect from 1 January 2013 are members of this 
scheme, where all employee pension deductions are 
paid to the Department of Public Expenditure and 
Reform.
By direction of the Minister for Health, no provision 
has been made in respect of benefits payable in 
future years in relation to the Local Government 
(Superannuation Revision) (Consolidation) Scheme 
1986 or the Single Public Service Pension Scheme.
In order to help meet the cost of benefits payable 
in future years, reserves have been split between 
retained reserves and superannuation reserves, which 
consist of employee superannuation contributions. 
This split is shown in note 12 - Movement on Income 
and Expenditure Reserves.    
       
     
       
  
L. Provisions      
 
A provision is recognised when the HPRA has a 
present obligation as a result of a past event, it is 
probable that this will be settled at a cost to the HPRA 
and a reliable estimate can be made of the amount of 
the obligation.  
M. Library      
 
No value has been placed on the books, audio-visual 
resources and electronic databases in the library.  
Expenditure on these items is written off in the year in 
which it is incurred.     
    
       
N. Leases      
 
All leases are treated as operating leases and the 
rentals thereunder are charged to the Statement of  
Income and Expenditure and Retained Revenue 
Reserves on a straight line basis over the lease period.  
       
      
O. Loans      
 
Loans are recognised initially at the transaction price 
(present value of cash payable, including transaction 
costs). Loans are subsequently stated at amortised 
costs. Interest expense is recognised on the basis 
of the effective interest method and is included in 
finance costs.
Loans are classified as current liabilities unless there is 
a right to defer settlement of the loan for at  least 12 
months from the reporting date.    
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Notes to the Financial Statements
For the year ended 31 December 2019
2. Property, plant Fixtures and Computer  Leasehold Improvements Premises Total 
 and equipment Fittings Equipment Improvements To Premises   
  € € € € € €
  Cost
  Balance as at    1,238,581         16,441,616             502,445           4,374,608      23,156,037    45,713,287
  1 January 2019  
  Additions for the year             85,977      1,387,110    271,016    -   -  1,744,103
  Disposals for the year (650) (115,420) -     -     -    (116,070)
  As at 31 December 2019       1,323,908  17,713,306 773,461 4,374,608 23,156,037 47,341,320
  Depreciation
  Balance as at    1,196,283 15,579,197 502,445 4,007,532  - 21,285,457
  1 January 2019
  Charge for the year             39,162 1,101,364 27,102 107,220  -  1,274,848
  Disposals for the year  (650) (114,789) -  -  - (115,439)
  As at 31 December 2019    1,234,795 16,565,772 529,547 4,114,752  - 22,444,866
  Net Book value at  
 31 December 2019             89,113 1,147,534 243,914  259,856 23,156,037 24,896,454
  Net Book value at 
  1 January 2019    42,298 862,419  - 367,076 23,156,037 24,427,830
3.  Income  2019  2018
  €  €
 Fee Income
 Clinical Trials    389,916      210,844  
 Human Medicine - National Fees    7,034,900           6,927,684  
 Human Medicine - European Fees    9,197,663           7,311,717  
 Veterinary Medicine - National Fees    1,988,373           1,856,343  
 Veterinary Medicine - European Fees    1,691,326           1,662,060  
 Compliance Department    5,845,249     4,925,873  
 Medical Devices    1,715,249           1,565,944   
  
    27,862,676         24,460,465  
 Movement in deferred revenue  70,200    (558,862) 
    27,932,876         23,901,603  
 Dept Of Health Funding (Vote 38 Subhead E1)    4,964,255          4,316,000   
 Other Income (Note 4)    805,824             888,884 
  
 Total Income    33,702,955        29,106,487  
 
Certain fees received by the Authority under the Irish Medicines Board Act 1995 (as amended), totalling €20,749,816  
in 2019, shall be paid into or disposed of for the benefit of the Exchequer in such manner as the Minister for Public  
Expenditure and Reform directs.   
   
The HPRA is in discussions with its parent department, as it is some years since the Minister has issued a directive in  
relation to the fees under Section 13 of the IMB Act.   
   
   
.
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Notes to the Financial Statements
For the year ended 31 December 2019
4.  Other Income
  2019  2018
  €  €
  
 Conference Fee Income    12,860      181,842  
 Deposit Interest    16,737                16,064  
 (Loss)/Gain on Disposal of Fixed Assets   49      (26)
 IT Income    714,875      614,250  
 Zambia Project Income   61,303     76,754 
   
   805,824   888,884
5.  Salaries and Wages    
 
 Basic Pay      19,622,110        18,265,668   
 Overtime      10,956             12,465  
 Allowances     178,300        169,636   
 Staff Short Term Benefits     19,811,366        18,447,769   
 Retirement Benefit Costs     1,153,648        885,825 
 Employer’s Contribution to Social Welfare     1,986,755        1,826,620   
 Employer’s Contribution to Single Scheme Pension     910,669       -
   
       23,862,438         21,160,214 
 
  
The average number of staff employed during the year was 348 (2018 - 332).   
Payroll numbers at 31 December 2019 can be analysed across the following departments:    
   
 
 Chief Executive  3  3
 Compliance  63  63
 Finance, Corporate & International  26  24
 Human Products Authorisation & Registration  101  101
 Human Products Monitoring  34  33
 Human Resources & Change  10  9
 IT & Business Services  18 21
 Medical Devices 44  36
 Quality, Scientific Affairs & Communications 12  13
 Veterinary Sciences  35  32
 Staff  346  335
 Authority Members 7  7
 Pensioners  46  39
  399  381
 
 
No termination or severance payments were made during the year. One such payment was made in 2018.  
Additional superannuation contributions for Public Servants of €755,591 were deducted from staff during the year and 
paid over to the Department of Health. On 1 January 2019, in accordance with DPER circular 21/2018, the pension related 
deduction (PRD) was replaced by an additional superannuation contribution (ASC).
Pension deductions for Public Servants who are members of the Single Public Service Pension Scheme of €336,275 were 
deducted from staff during the year and paid over to the Department of Public Expenditure and Reform.
In agreement with our parent department and DPER, the HPRA have also paid over Single Scheme employer 
contributions since January 2019 for employees not employed in exchequer funded areas.   
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For the year ended 31 December 2019
 Salary Band 2019  2018
  
 €0 to €60,000    214  213
 €60,001 to €70,000    54  47 
 €70,001 to €80,000    20  27 
 €80,001 to €90,000    16  11 
 €90,001 to €100,000    20  20 
 €100,001 to €110,000    15  10 
 €110,001 to €120,000    4  4 
 €120,001 to €130,000    2  1 
 €130,001 to €140,000    -  1 
 €140,001 to €150,000    -  -
 €150,001 to €160,000    1 1 
     
    346  335  
 
 Average Salary    €54.9K  €54.6K 
 
Higher salaries relate primarily to scientific and other professional staff e.g. clinicians, pharmacists, veterinarians, lawyers 
etc and are in accordance with Department of Health salary scales.
For the purposes of this disclosure, short-term employee benefits in relation to services rendered during the reporting 
period include salary, overtime, allowances and other payments made on behalf of the employee, but exclude employer’s 
PRSI.   
  
6.  Operating Costs
  2019  2018
  €  €
  
 Accommodation Costs     1,291,822       1,210,891  
 Travel, Representation and Training    973,179       1,304,837 
 Bank Charges and Interest    179,047        187,696  
 Legal Fees    2,344,387        657,437  
 Audit Fees (External and Internal)    34,305        32,791  
 Stationery, Publications, Postage and Communications     464,148        578,144   
 Consultancy     499,038        331,390   
 Sampling and Analysis    243,132                     252,748   
 IT Costs    1,342,133                     1,645,426  
 Document Storage    152,279                     123,707   
 Telephone and Telecommunications    97,616                     92,593   
 Movement on Bad Debt Provision     18,287                 (532,095)  
   
   7,639,373               5,885,565  
  
Travel costs include an amount of €26,162 related to staff hospitality, and an amount of €432,060 related to travel and 
subsistence, of which €198,851 is national and €233,209 is foreign.
No costs were incurred in relation to client hospitality.
Legal fees are in relation to ongoing legal proceedings, and do not include any amounts in relation to conciliation, 
arbitration or settlement payments.
Consultancy costs comprise €127,669 related to public relations/marketing, €194,541 related to human resources/
pensions and €176,828 related to other.
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Employee’s short term benefits are categorised into the following bands:
Notes to the Financial Statements
For the year ended 31 December 2019
7.  Debtors (all due within one year) 2019  2018
  €  €
 
 Trade Debtors    2,018,140      1,852,256  
 Prepayments   309,093                   211,940  
 Other Debtors    187,751      134,144  
   
    2,514,984      2,198,340 
Trade debtors are shown net of the bad debt provision.
8. Creditors (amounts falling due within one year)   
 
 
 Trade Creditors    1,174,870                  189,511 
 Accruals    8,692,902      8,129,067  
 Deferred Revenue    1,738,297                1,808,497  
 Revenue Commissioners               687,018                  633,837   
  
          12,293,087                10,760,912  
9. Cash and Cash Equivalents    
  
  
 Cash at Bank and in Hand       772,549    4,027,728 
 Demand Deposits (Convertible to Cash on Demand)       1,518,271         6,134,827 
 
             2,290,820        10,162,555  
 
10. Short Term Deposits     
 
 
 Short Term Deposits (not immediately convertible to cash)    17,658,240           8,216,814  
  
           17,658,240             8,216,814  
 
11. Administration Expenses    
 
 Surplus for the year was calculated having charged:    
 Auditor’s Remuneration   20,000  18,000
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For the year ended 31 December 2019
12.   Movement on Income and  
    Expenditure Reserves 
    As At  Income &  Transfer To As At 
   01/01/2019  Expenditure   Pension Reserve  31/12/2019 
    € €  € € 
  
  Retained Reserves     18,611,970 926,296  (400,000) 19,138,266  
Staff Superannuation Contributions            10,876,143 691,855  400,000 11,967,998   
 
        29,488,113  1,618,151   0 31,106,264   
Our Audit and Risk Committee recommended the transfer of a further €400,000 in 2019 from retained reserves to the  
superannuation reserve as a result of a number of recent and upcoming retirements, where the costs are quite 
significant.     
   
 
13. Long Term Liabilities   
    
  Mortgage
On 22 December 2004 the HPRA purchased its premises at Kevin O’Malley House, Earlsfort Centre, Earlsfort Terrace, 
Dublin 2. The purchase was financed by way of a mortgage, secured on the premises of €20,400,000 over 20 years from 
Bank of Ireland Corporate Lending.    
    
The HPRA is committed to making the following capital repayments on its mortgage:   
     
    
 
  2019  2018
      €  € 
 
  - within one year             793,332               793,332 
  - between one and five years          3,173,328            3,173,328 
  - after five years     20            793,352  
   
        3,966,680      4,760,012  
14. Interest Rate Exposure   
 
The HPRA have taken all necessary steps to minimise its interest rate exposure by fixing 2/3s of the borrowings for the 
mortgage duration. The balance of the borrowings are fully offset by cash reserves. As the mortgage is at a fixed rate, 
the Authority has no interest rate exposure.     
 .     
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15. Financial Commitments
 Accommodation Costs (Note 6) includes expenditure of €285,984 in relation to operating leases.  
   
 On 28 January 2005 the HPRA signed a leasehold interest in respect of the 5th floor, 6 Earlsfort Terrace, Dublin 2.  
 At 31 December 2019 this lease had 2 years and 4 months remaining. 
    
  2019  2018
   €  €
 The amounts due under this lease are as follows:
 - within one year  285,984   285,984
 - between one and five years    381,312      667,296  
 - after five years  -   -
   
    667,296       953,280  
 On 11 June 2019 the HPRA signed a leasehold interest in respect of the 4th floor, 6 Earlsfort Terrace, Dublin 2.  
The lease included a seven month rent free period to 10 January 2020. At 31 December 2019 this lease had 14 years 
and 5.5 months remaining. 
 
   
   
 The amounts due under this lease are as follows:
 - within one year   360,735    -
 - between one and five years     1,485,683       - 
 - after five years   3,508,230    -
   
     5,354,648        - 
16. Capital Commitments   
     
 Contracted For (Contract Signed)      26,779     1,404,356  
   
      26,779     1,404,356  
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17. Authority Remuneration 2019  2018  
  Fees  Expenses
   €  €
  
 Ms. Ann Horan (Chairperson)           11,970               0 
 Mr. Pat Brangan             7,695                 0
 Mr. Wilfrid Higgins            7,695                 0 
 Mr. David Holohan           7,695               78 
 Mr. Brian Jones             7,695                 184
 Dr. Elizabeth Keane           7,695               522
 Prof. David Kerins  0 192
 Prof. Caitriona O’Driscoll             0                 692 
 Dr. Diarmuid Quinlan            7,695                 235
   
     58,140       1,903  
Up to the 15th February 2017, other than the Chairperson, no other Authority Member received a salary. On 16th 
February 2017, the Health (Miscellaneous Provisions) Act was enacted, which made provision for payment of fees 
to other Authority members, provided that they were in compliance with the ‘one person one salary’ principle. Two 
Authority members do not receive a fee under this principle.
Authority expenses comprise €1,719 domestic and €184 foreign.  
 
18. Key Management Personnel Remuneration €  €
    
 Chief Executive   157,031   151,500
 Senior Management   812,419     832,051 
   
     969,450       983,551  
  
  
All payments to key management personnel were in respect of salaries and short term employee benefits. No post-
employment benefits or termination benefits were paid.
The Chief Executive’s and senior management’s pension entitlements do not extend beyond the standard entitlements 
in the model public sector defined benefit superannuation scheme.   
   
 
19. Related Party Transactions
  
The HPRA adopts procedures in accordance with the guidelines issued by the Department of Public Expenditure and 
Reform (DPER) covering the personal interests of Authority members. A register of such interests is maintained. In 
addition to the DPER guidelines, as a regulator the HPRA has strict conflict of interest and disclosure requirements in 
relation to any interactions with a regulated body, which are updated annually. There have been no transactions with 
related parties which require disclosure under Financial Reporting Standard 102.
20. Prompt Payment of Accounts
  
 The Health Products Regulatory Authority (HPRA) confirms that it is complying with EU law in relation to prompt 
payment of accounts.
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21. Exchange Rates
  
 The exchange rates used in preparing these financial statements were as follows: 
  2019 €1 = STG £0.85369
 2018       €1 = STG £0.85680
22. Provisions
 
The HPRA has been notified of a number of legal proceedings or potential proceedings. The Authority has provided 
in full for its ‘best estimate’ of the expenditure it is likely to incur in relation to those cases. The Authority is availing of 
the reduced disclosures allowed by FRS 102 in instances where full disclosure might prejudice seriously its position in a 




The HPRA has a reasonable expectation, at the time of approving the financial statements, that the HPRA has adequate 
resources to continue its operations. For this reason, the HPRA continues to adopt the going concern basis in preparing 
the financial statements.
The Covid-19 pandemic has impacted how the HPRA operates, with all staff substantially moved offsite and resources 
diverted to managing implications of the pandemic. The Authority assesses this event to be a non-adjusting post 
balance sheet event in relation to the 2019 financial results. No impact is expected in relation to the 2019 financial 
statements and currently we are not predicting a significant financial impact for 2020, although due to the nature of 
the pandemic, the final impact cannot be estimated at this point. HPRA’s income is derived from the pharmaceutical, 
medical devices and related industries, which continue to operate throughout the pandemic and therefore are 
financially less impacted than those industries which have closed or have limited output.   
      
 
24. Approval of Financial Statements
  
 The financial statements were approved by the Authority of the HPRA on 07 May 2020.
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Educational / Professional Development Presentations and Training 
Institution Course Presentation Title
BVL (Germany) Training on Quality Assessment of 
Veterinary Medicines
New Veterinary Legislation - Focus on 
Quality Aspects
DCU Chemistry / Pharmaceutical 
Chemistry
Regulatory Affairs and Risk 
Management
DCU / TCD Bioprocess Engineering Regulation of Medicines
DCU / TCD Bioprocess Engineering Regulation of Biologics
GMIT Medtech Regulatory Affairs New European Regulations on 
Medical Devices
GMIT Medtech Regulatory Affairs Medical Devices Regulation – An 
Introduction
Infarmed / ANSM Training Workshop Update on JAMS WP5 Clinical 
Process and resource Development
IPPOSI Patient Education Programme Various Presentations: Regulatory 
Affairs, Medicinal Product Safety and 
Pharmacovigilance
Irish Designated Veterinarians 
Group / UCD
Training Workshop Responsibilities of Designated 
Veterinarians
LAST Ireland Laboratory Animal Science and 
Training 
HPRA Implementation of Directive 
2010/63/EU 
Law Society of Ireland Diploma in Healthcare Law Regulating Health Products - The 
HPRA
Letterkenny IT Veterinary Nursing The Regulation of Veterinary 
Medicines in Ireland
Pharmacists in Industry, Education 
and Regulatory
Autumn CPD Meeting and AGM Multi Stakeholder Approach to 
Managing Shortages
RCSI Nurse / Midwife Prescribing The Role of the HPRA and 
Pharmacovigilance
St John’s Cork Veterinary Nursing The Regulation of Veterinary 
Medicines in Ireland
Swiss Medic GMP Training for Inspectors Reprocessing and Reworking
TCD Bioengineering Regulation of Medical Devices





TCD Immunotherapeutics Regulation of Medicines
TCD Immunotherapeutics Regulation of Biologics
TCD Pharmaceutical Manufacturing 
Technology
HPRA and the Role of the 
Pharmacopoeia in the Regulation of 
Medicines
TCD Pharmaceutical Medicine Regulation of ATMPs
TCD Pharmaceutical Medicine Adverse Event / Reaction Reports 
arising from Clinical Trials
TCD Pharmaceutical Medicine Pharmacovigilance Inspections
TCD Pharmaceutical Medicine Overview of Pharmacovigilance
TCD Pharmaceutical Medicine Pharmacovigilance and Risk 
Management
TCD Pharmaceutical Medicine Communication of Drug Safety Data 
& Overview of the WHO Programme 
for International Drug Monitoring
TCD Pharmaceutical Medicine Workshop: Completion of Individual 
Case Reports (SUSARs and ICSRs)
TCD Pharmaceutical Medicine EU Falsified Medicines Directive
TCD Pharmaceutical Medicine GCP Inspections
TCD Pharmaceutical Medicine Product Recalls and MA Withdrawals
TCD Pharmacy Overview of Pharmacovigilance
TCD Pharmacy Quality Defect Reporting Workshop  
TCD Pharmacy Quality Defect Reporting, 
Investigations and Recall 
Management Workshop
London School of Hygiene & 
Tropical Medicine
Vaccines Short Course Licensing Vaccines: Clinical 
Considerations
The State Laboratory Training Seminar HPRA Enforcement
TOPRA Training Workshop Medical Devices Legislation
UCD Clinical Biomarkers (Medicine) Overview of the IVD Regulation
UCD Medicine / Pharmacy Notification of Adverse Reactions
UCD Prescribing Medication The Role of the HPRA and 
Pharmacovigilance
UCD Regulatory Affairs Regulation of Clinical Trials
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Event / Organiser Presentation Title
ACB Scientific Meeting Role of the HPRA in IVD Regulation
Analytical Technologies Europe 2019 - CASSS Post-Approval Flexibility in Analytical Methods
An Garda Síochána - Seminar Enforcement of Online Sales of Medicines
Animal and Plant Health Association Veterinary Medicines – An Update on Regulatory 
Issues
Animal Health Awards HPRA Introduction
ANSM JAMS WP5 – Update on Outputs
BioPharmaChem Ireland – Data Analytics Workshop Data Analytics and GMP – A Regulatory Perspective
Centre for Cell Manufacturing Ireland Regulatory Developments for ATMPs
Clinical Research Development Ireland HPRA supports for Clinical Research
DIA Brexit Summit Centralised Activities – Ireland: Challenges and 
Preparedness
European Commission/ ECDC – One Health AMR 
Country Visit
Medicines Regulation: Opportunities to Contribute 
to Addressing AMR
European Medicines Agency New Approaches to Improve Benefit-risk Assessment 
of Veterinary Medicinal Products
FSAI An Overview of the Cosmetovigilance System
G2 Risk Summit Combating Online Medical Product Crime through 
Operation Pangea
GIRP (European Healthcare Distribution Association) Overview on the ‘Use and Learn Phase’ of FMD in 
Ireland
Global Pharmaceutical Manufacturing Leadership 
Forum
PIC/S GMP Inspection Reliance Initiative
Health Research Board Controlled Drugs Overview
IMSTA Brexit Preparedness – HPRA Perspective
Information Day: EU Commission Public Health 
Programme
Joint Action on Market Surveillance of Medical 
Devices
Irish Cosmetic and Detergent Association Cosmetic Products - A Regulatory Overview
Irish Exporters Association Patient Safety and the Supply Chain
Irish German Healthcare Forum Implementation of the EU Device Regulations
Irish Medtech Association Implementation of the EU Device Regulations
Irish Medtech Association Implementation of the EU Medical Devices 
Regulations
Irish Ringers Meeting Role of the HPRA in Wildlife Research
Klifovet AG & AnimalhealthEurope New EU Veterinary Medicines Regulation
Medico-Legal Society of Ireland Medicrime in a Cyber World
OCLAESP (France) Operation MISMED 2: Results and Observations from 
Ireland
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OMCL Network Annual Meeting HMA Risk Assessment and Test Recommendation 
Tool
OMCL Network Annual Meeting – CAP Update on Heparin Crude Surveillance Activities
Parenteral Drug Association (PDA) Annex 1 Revision
Parenteral Drug Association (PDA) Demonstrating the Effectiveness of the PQS from a 
QRM Perspective
Parenteral Drug Association (PDA) PIC/S GMP Inspection Reliance Initiative
PIC/S Annual Seminar Application of Quality Risk Management to 
Inspection Planning for Sterile Site Inspection
PIC/S Expert Circle Meeting Cross Contamination Considerations – Introducing 
Mew Molecule into a Facility
PLS Pharma Responsible Person Forum HPRA: Expectations and Deficiencies
Premier Irish Industrial Hemp Conference Application Process for a Licence to Cultivate Hemp
QP Forum – TCD ICH Q12 – What it might mean for QPs
QP Forum – TCD Regulatory Updates
Research Quality Association – Forum Safety Features
Revenue Customs Service - Seminar Enforcement of Online Sales of Medicines
Taking Care of Business (DBEI) Supporting Innovation through Regulation and 
Science
TOPRA Annual Symposium A Regulators Perspective on ICH Q12
TOPRA Annual Symposium Brexit Checklist
TOPRA Annual Symposium Clinical Data Requirements with the MDR – 
Competent Authority Perspective
TOPRA Annual Symposium Clinical Trials Regulation
TOPRA Annual Symposium Guidance on Quality Requirements for Drug–Device 
Combinations
TOPRA Annual Symposium Horizon Scanning within the EU-Innovation Network
TOPRA Annual Symposium Horizon scanning within the EU-Innovation Network
TOPRA Annual Symposium Implementation of the Device Regulations – An 
Overview
TOPRA Annual Symposium IVDR Preparedness – National Competent Authority 
Perspective
TOPRA Annual Symposium Medical Devices Post-market Surveillance
TOPRA Annual Symposium New Veterinary Medicines Regulation - Impact on the 
Authorities
TOPRA Annual Symposium New Veterinary Medicines Regulation – The Impact 
on Authorities
TOPRA Annual Symposium Novel Veterinary Medicines Development: A CVMP 
Perspective 
TOPRA Annual Symposium Progress on MDR/IVDR – Competent Authority 
Perspective
TOPRA Annual Symposium Veterinary Medicines – Life after Brexit






– Lemtrada (alemtuzumab) – Use restricted while European Medicines Agency (EMA) 
review is ongoing
– SGLT-2 inhibitors – Risk of Fourniers Gangrene 
– Cobicistat boosted darunavir and elvitegravir – Avoid use in pregnancy due to potential 
risk of virological failure in second and third trimester
– Direct-Acting Antivirals for chronic hepatitis C – Risk of hypoglycaemia in patients with 
diabetes
– Biotin – Interference with clinical laboratory tests
– Direct Healthcare Professional Communications published on the HPRA website since the 
last Drug Safety Newsletter
June 
93rd Edition
– Domperidone containing medicines – No longer approved for use in children due to lack 
of efficacy
– Direct oral anticoagulants (DOACs) – Not recommended in patients with 
antiphospholipid syndrome (APS) due to possible increased risk of recurrent thrombotic 
events
– Xelijanz (tofacitinib) – Use restricted in patients at high risk of pulmonary embolism while 
European Medicines Agency (EMA) review is ongoing
– Direct Healthcare Professional Communications published on the HPRA website since the 
last Drug Safety Newsletter
August
94th Edition
– Montelukast – Reminder of the risk of neuropsychiatric reactions and product information 
update
– Modafinil-containing medicines – Potential risk of congenital malformations when 
administered during pregnancy
– RoActemra (tocilizumab) – Rare risk of serious hepatic injury including acute liver failure 
requiring transplantation
– Febuxostat – Increased risk of cardiovascular death and all-cause mortality in patients 
treated with febuxostat in the CARES study
– Darzalex  (daratumumab) – Risk of Hepatitis B reactivation
– Direct Healthcare Professional Communications published on the HPRA website since the 
last Drug Safety Newsletter
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December
95th Edition
– Methotrexate – New measures to avoid dosing errors
– SGLT2 inhibitors – Updated advice on monitoring ketone bodies in patients hospitalised 
for major surgical procedures or acute serious medical illnesses
– Ingenol mebutate (Picato ) – Use with caution in patients with a history of skin cancer
– Fingolimod (Gilenya ) – Contraindication in pregnant women and in women of child 
bearing potential not using effective contraception
– Levothyroxine – Close monitoring recommended in the event of a brand change
– Parenteral nutrition products for neonates and children below 2 years of age – Protect 
from light until administration is completed
– Direct Healthcare Professional Communications published on the HPRA website since the 
last Drug Safety Newsletter
Human Medicines Articles – External Publications
Month Publication Topics
January MIMS – Fluoroquinolone antibiotics – EU review advises restrictions 




– Adverse Reaction Reporting – Reminder
February MIMS – Mycophenolate – Reminder of updated contraceptive advice
MIMS Respiratory 
Supplement
– Fluoroquinolone antibiotics – EU review advises restrictions 
for certain infections and warns of rare but serious long 
lasting adverse reactions
March IMF – Fluoroquinolone antibiotics – EU review advises restrictions 
for certain infections and warns of rare but serious long 
lasting adverse reactions
MIMS – SGLT-2 inhibitors – Risk of Fournier’s gangrene
MIMS Cardiovascular 
Supplement
– Clarithromycin – Reminder on cardiovascular safety and risk 
minimisation advice
April MIMS – Valproate (Epilim) – Reminder about contraindications, 




– Adverse Reaction Reporting
May MIMS – Direct-Acting Antivirals for Chronic Hepatitis C – Risk of 
hypoglycaemia in patients with diabetes
MIMS Oncology 
Supplement
– Hydrochlorothiazide (HCTZ) – Risk of non-melanoma skin 
cancer (NMSC)
June MIMS – Insulin-containing products – Risk of medication errors 
associated with extraction of insulin from pre-filled pens and 
cartridges for reusable pens
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July / August MIMS – Systemic fusidic acid and interaction with statins – Reminder 
of risk of rhabdomyolysis
MIMS Respiratory 
Supplement 
– Montelukast – Reminder of risk of neuropsychiatric reactions 
and product information update
September IMF – Domperidone-containing medicines – No longer approved 
for use in children due to lack of efficacy




– Gabapentin – Respiratory depression without concomitant 
opioid use
October MIMS – Domperidone-containing medicines – No longer approved 
for use in children due to lack of efficacy
MIMS Women’s Health 
Supplement
– Fingolimod (Gilenya ) – Contraindicated in pregnant women 
and in women of child bearing potential not using effective 
contraception
November MIMS – Picato – Use with caution in patients with a history of skin 
cancer
MIMS Type 2 Diabetes 
Supplement
– SGLT2 inhibitors – Updated advice on monitoring ketone 
bodies in patients hospitalised for major surgical procedures 
or acute serious medical illnesses
December MIMS – Parenteral nutrition products for neonates and children 
below 2 years of age – Protect from light until administration 
is completed
MIMS Compendium – Methotrexate – New Measures to Avoid Dosing Errors
Veterinary Medicines Articles – External Publications 
Publication Article Title
Veterinary Ireland Journal Initial Assessment of the Impact of the New European Regulation on 
Veterinary Medicines 
It’s Your Field Regulatory Controls on the Supply of Veterinary Medicines in Ireland
It’s Your Field Authorisation of Veterinary Medicines in Ireland
It’s Your Field Veterinary Pharmacovigilance
It’s Your Field The Role of The HPRA in Animal Research in Ireland
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Committee/Working Group Organisation Meetings 
in 2019
Counterfeiting of Medical Products (CMED) Council of Europe 1




Controlled Drugs Cross Border Group Department of Health 2
Early Warning and Emerging Trends Group Department of Health 4
Medical Cannabis Access Programme Department of Health 5
National Clinical Effectiveness Committee (NCEC) Department of Health 1
Safety Features on Medicines – National Coordination Group Department of Health 10
National Interdepartmental AMR Consultative Committee Departments of Health 
/ Agriculture, Food 
and the Marine
1
Committee for Cosmetics and Consumer Health EDQM 3
Committee for Cosmetics and Consumer Health and European 
Network of OCCLs – Joint meeting
EDQM 1
European Network of Official Cosmetics Control Laboratories 
(OCCL)  
EDQM 1
OMCL Network Active Pharmaceutical Ingredient (API) Working 
Group
EDQM 1
OMCL Network Advisory Group EDQM 1
OMCL Network Centrally Authorised Products (CAP) Working 
Group
EDQM 1
OMCL Network Falsified Medicines Working Group EDQM 2
OMCL Network Mutual Recognition and Decentralised procedures 
(MRP/DCP) Working Group
EDQM 1
Committee for Advanced Therapies (CAT) EMA 11
Committee for Herbal Medicinal Products (HMPC) EMA 5
Committee for Medicinal Products for Human Use (CHMP) EMA 11
Committee for Medicinal Products for Veterinary Use (CVMP) EMA 11
Committee for Orphan Medicinal Products (COMP) EMA 11
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European and National Committee / 
Working Group Participation
Committee/Working Group Organisation Meetings 
in 2019
Good Clinical Practice (GCP) Inspectors’ Working Group (including 
training seminar) 
EMA 1
Good Manufacturing and Distribution Practice (GMDP) Inspectors’ 
Working Group / Sub-group
EMA 4
Heparin Working Group EMA 3
Management Board EMA 4
Opioid Initiative Steering Committee  EMA 2
Paediatric Committee (PDCO) EMA 12
Pharmacovigilance (PV) Inspectors’ Working Group EMA 1
Pharmacovigilance Risk Assessment Committee (PRAC) EMA 11
Pharmacovigilance Working Party - Veterinary EMA 3
Quality Defects - Best Practices Working Group EMA 1
Quality Defects and Rapid Alert Working Group EMA 2
Quality Working Party EMA 2
Scientific Advice Working Party - Human EMA 11
Scientific Advice Working Party – Veterinary EMA 11
Signal Management Review Technical Working Group (Methods) – 
PRAC 
EMA 4
Signal Management Review Technical Working Group (SMART) 
Processes – PRAC 
EMA 5
Veterinary Medicines Regulation – Drafting of implementing Acts EMA 4
Competent Authorities for Organ Donation and Transplantation European Commission 1
Competent Authorities for Tissues and Cells European Commission 1
Expert Group on Clinical Trials European Commission 4
Expert Group on Precursor Chemicals European Commission 2
Expert Working Group on Safety Features (meetings, telecons & 
workshop with EMVO)
European Commission 8
IVD Classification Working Group European Commission 7
IVD Technical Group European Commission 4
IVD-CIE Working group European Commission 3
Joint Action Market Surveillance of Medical Devices (MDs) 
(including telecon)
European Commission 6
Medical Device – Vigilance MIR Form Development European Commission 4
Medical Device Clinical Investigation and Evaluation Working 
Group
European Commission 2
Medical Device Compliance and Enforcement Working Group 
(COEN) 
European Commission 2
Medical Device Coordination Group European Commission 6
Medical Device Expert Group Vigilance Working group European Commission 2
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Committee/Working Group Organisation Meetings 
in 2019
Medical Device Periodic Safety Update Reports Working Group European Commission 2
Medical Device Regulatory Committee European Commission 1
Medical Device Vigilance Eudamed Working Group European Commission 2
National Contact Points for the implementation of Directive 
2010/63/EU
European Commission 2
New Emerging Technologies - Software WG European Commission 1
Nomenclature Taskforce European Commission 2
Notified Body Operations Group European Commission 4
NBO Taskforce – Sampling European Commission 3
Organ Registries European Commission 1
Platform of European Market Surveillance Activities in Cosmetics 
(PEMSAC) – Market Surveillance
European Commission 1
Standing Committee on Cosmetic Products European Commission 2
Sub-group on Borderline Issues relating to Cosmetics European Commission 1
Unique Device Identifier European Commission 5
Working Group on Cosmetic Products European Commission 3
Interpretation Guide for Harmonised Assessment Checklist for 
Audits of GMP Inspectorates  
European Commission 
/ EMA / HMA / PIC/S
3
Authorisation of Preparation Process for Blood, Tissues and Cells 
(GAPP Work Package Five) 
European Commission 
/ National Competent 
Authorities
2
Inspections Expert Subgroup (IES) Work Cluster IV (Blood, Tissues 
and Organs)
European Commission 
/ National Competent 
Authorities
1
SoHO Vigilance Expert Sub-group (VES) (Blood, Tissues & Cells 
and Organs)
European Commission 
/ National Competent 
Authorities
2
Operations / Liaison Meetings Europol 6
Food Fraud Task Force Food Safety Authority 
of Ireland (FSAI)
2
Clinical Trials Facilitation Group (CTFG) HMA 6
Co-ordination Group for Mutual Recognition and Decentralised 
procedures – Veterinary (CMDv)
HMA 11
Co-ordination Group for Mutual Recognition and Decentralised 
procedures – Human (CMDh)
HMA 11
Heads of Medicines Agencies Biannual Meetings HMA 2
Homeopathic Medicinal Products Working Group HMA 2
Management Group (including telecons) HMA 15
Pharmacovigilance Work-sharing Procedures Working Party HMA 11
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Committee/Working Group Organisation Meetings 
in 2019
Risk-based Surveillance Testing – Drafting Group (including 
telecons)
HMA 5
Working Group of Communications Professionals HMA 2
Working Group of Enforcement Officers (WGEO) (including 
management committee)
HMA 4
Working Group of Quality Managers HMA 2
Operational Group on Borderline and Combination Products HMA / CAMD 1
EU Innovation Network (EU-IN) HMA / EMA 2
National Cosmetics Surveillance Forum HSE / HPRA 4
International Coalition of Medicines Regulatory Authorities 
(ICMRA)
ICMRA 2
Innovation Network ICMRA 3
International Medical Device Regulators Forum (IMDRF) 
Management Committee
IMDRF 1
Revision of ICH Q9 Guideline International Conference 
on Harmonisation
4
Operation Pangea / Liaison Meetings Interpol 5
Competent Authorities for Medical Devices (CAMD) National Competent 
Authorities
2




Permanent Forum on International Pharmaceutical Crime (PFIPC) PFIPC 2
Pharmaceutical Inspection Co-Operation Scheme (PIC/S) 
Committee of Officials
PIC/S 1
PIC/S Expert Circle on Quality Risk Management (QRM) (including 
training seminar and telecons)
PIC/S 13
PIC/S Sub-Committee on Compliance (including telecon) PIC/S 2
PIC/S Sub-Committee on Harmonisation PIC/S 4
National Immunisation Advisory Committee RCPI / Department of 
Health
3
Expert Group meeting on Falsified Medicinal Products UN Office of Drugs and 
Crime
1
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